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ABSTRACT 
 
Hyperphagia emerges suddenly after 22 days of age in Zucker fatty (fa/fa) rats, 
and fatties become visibly obese within days.  This rapid increase in growth rate is likely 
to be associated with substantial changes in glucose metabolism.  The objective of these 
experiments was to determine the relationship between insulin resistance and the onset of 
hyperphagia.  Insulin tolerance tests showed that fatties were remarkably insulin resistant 
prior to the onset of hyperphagia, hyperinsulinemia, and obesity, but become as insulin 
sensitive as their lean littermates after the onset of hyperphagia.  Furthermore, fatties 
became increasingly insulin resistant prior to the onset of hyperphagia, and then became 
as insulin resistant as their lean littermates after the onset of hyperphagia.  To determine 
whether these changes in insulin resistance are associated with changes in expression of 
the nuclear transcription receptor peroxisome proliferator-activated receptor gamma 
(PPARγ), which improves insulin resistance by increasing lipogenesis in adipose tissue, 
we measured PPARγ and fatty acid synthase (FAS) mRNA and protein at several points 
in development.  PPARγ and FAS mRNA expression was induced in fatties after the 
onset of hyperphagia.  PPARγ and FAS protein expression increased gradually after the 
onset of hyperphagia, similar to the changes in insulin sensitivity.  These observations 
suggest that changes in PPARγ signaling may play a critical role in promoting the 
increase in insulin sensitivity after the onset of hyperphagia and perhaps in the promotion 
of hyperphagia itself. 
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PART 1.  INTRODUCTION 
  2
The obesity epidemic in the United States has been accompanied by an alarming 
increase in the prevalence of overweight children (1).  Data from the National Health and 
Nutrition Examination Survey (NHANES) indicate that the number of overweight 
children has increased among all age, race, and sex groups.  Overweight children are at 
high risk for becoming overweight adults and developing hypertension and type II 
diabetes (2).  These observations underscore the importance of understanding the early 
development of energy balance regulatory systems, particularly during critical periods of 
rapid growth. 
The Zucker fatty (fa/fa) rat is a unique model for the early development of 
obesity.  Fatties grow at the same rate as their lean littermates for the first 22 days of age 
(3).  At 23 days of age, fatties develop robust hyperphagia, which dramatically increases 
growth rate and expansion of fat mass (3).  Such a rapid increase in growth is likely to be 
accompanied by a fundamental change in regulation of glucose metabolism.   
There are gradual changes in glucose metabolism during development of obesity.  
As juvenile fatties accumulate excess adipose mass, they become increasingly insulin 
resistant.  When insulin resistant adult fatties are treated with the thiazolidinedione (TZD) 
rosiglitazone (4; 5), they become more insulin sensitive.  Rosiglitazone binds to 
peroxisome proliferator-activated receptor gamma (PPARγ), a transcription factor that 
belongs to the nuclear hormone receptor family responsible for control of adipocyte gene 
expression and differentiation, and glucose homeostasis.  PPARγ is expressed 
predominately in adipose tissue (6).  This transcription factor improves insulin sensitivity 
by upregulating genes for glucose uptake and lipogenesis in adipose tissue.  As a result, 
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TZDs promote elevated food consumption and increase lipogenesis in the Zucker fatty 
rats (4; 5) and in humans with  diabetes (7) . 
PPARγ mRNA expression in adipose tissue increases during the suckling period, 
reaches a plateau after weaning, and does not change thereafter (8).  The same increase in 
PPARγ occurs whether pups are weaned onto high fat or high carbohydrate diets.  In 
contrast, fatty acid synthase (FAS) mRNA is low during suckling and increases only 
when pups are weaned onto a high carbohydrate diet.  This rise in FAS mRNA is driven 
by a sharp increase in insulin.  When animals are weaned onto a high fat diet, insulin 
levels remain low, and FAS mRNA is undetectable.  These results indicate that PPARγ 
expression is developmentally regulated and that FAS is regulated by diet composition 
(8; 9).  These observations suggest that an increase in PPARγ-mediated insulin sensitivity 
could also play a role in the emergence of hyperphagia in fatties during the weaning 
transition.   
The purpose of these studies was to characterize the relationship between insulin 
resistance and the emergence of hyperphagia in fatty rats.  An initial series of 
experiments characterized changes in insulin sensitivity under several developmental 
conditions.  Secondly, we evaluated the activation of the PPARγ and FAS expression at 
various ages, using real time-polymerase chain reaction (RT-PCR) assay and Western 
blot analysis, relative to the onset of hyperphagia in the fatty rats.   
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PART 2.  LITERATURE REVIEW 
  5
Adult and Childhood Obesity  
Epidemiology and characterization 
Body fat ordinarily accounts for 25% of weight in women and 18% in men.  
Adults with an excess amount of body fat are classified as either overweight or obese, 
depending on the amount of excess body fat (10).  According to the National Center for 
Health Statistics, approximately 64% of Americans are either overweight or obese (11). 
This problem is not exclusive to the United States; the World Health Organization 
(WHO) has reported that obesity is a health concern in other developed countries as well 
(12).  As a result, the WHO has characterized obesity as a global epidemic. 
Medical hazards and chronic diseases associated with obesity have been 
increasingly well documented in recent years, and obesity has been conceptualized as a 
chronic disorder (13).  In adults, increased adiposity is associated with an increased risk 
for cardiovascular disease, type 2 diabetes, and several cancers (14).  It was recently 
estimated that obesity contributes to 300,000 deaths per year in the United States and cost 
our nation over $100 billion a year in direct and indirect cost (15-17). 
Body mass index (BMI) is used as a screening tool for the classification of 
individuals as normal weight, overweight, or obese.  It is widely used primarily because it 
is easy to calculate, noninvasive, and inexpensive; BMI is body weight in kilograms 
divided by height in meters squared.  Current guidelines consider a BMI of 25 to be 
overweight and a BMI more than 30 to be obese (15).  While BMI is a convenient 
screening tool, it has several limitations.  It can overestimate body fat in individuals who 
  6
are muscular and underestimate body fat in individuals who have lost muscle mass, such 
as the elderly.  The relationship between adipose mass and BMI can also vary among 
ethnic groups.  For these reasons, it may be necessary to estimate body fat by more direct 
measures, such as skin-fold thickness, underwater weighing, or dual energy X-ray 
absorptiometry, to determine whether someone actually has excess body fat. 
Childhood prevalence and significance 
The obesity epidemic has been accompanied by an alarming increase in the 
prevalence of overweight children (1; 2).  Currently, statistical percentiles are used to 
classify children as at risk for overweight.  These guidelines define children at or above 
the 85th percentile BMI to be at risk for overweight and those at or above the 95th 
percentile to be overweight (18).  Because BMI changes as a function of age, BMI 
growth curves for children published by the Centers for Disease Control and Prevention 
(CDC) are used to chart an individual child’s BMI relative to the population (19).  
According to data from the National Health and Nutrition Examination Survey 
(NHANES), the number of obese children in United States has doubled in the last two 
decades (1; 20).  Currently, 15.3% of 6 to 11 year olds and 15.5% of 12 to 19 year olds 
are at or above the 95th percentile for BMI on the CDC growth charts. 
It is rare that mortality of children relates to body fat, but the contribution of 
excess body fat to morbidity in children is increasing.  The obese child can suffer from 
serious morbidity, including hyperlipidemia, type 2 diabetes, orthopedic, neurological, 
pulmonary, gastroenterological, and endocrine complications (21; 22).  Overweight also 
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contributes to early pubertal development in girls and delayed pubertal development in 
boys (23-25).  Aside from the physiological constraints, children often suffer from the 
psychological repercussions associated with overweight and obesity, such as teasing and 
discrimination (22; 26).  With advancing age, obesity also promotes physical, economic, 
and emotional hardship (27).  In most circumstances, the complications from childhood 
obesity do not become a major health burden until decades later, although the medical 
consequences may still exist early in life (13; 28).  Numerous studies have demonstrated 
a correlation between childhood morbidity and adulthood morbidity and mortality (29).  
Approximately 25 - 50% of obese adolescents will become obese adults (22).  Moreover, 
the pathological processes and long term risk factors beginning in childhood may be 
more detrimental for adults who became obese as children than the 30% of obese adults 
who were not obese during childhood (18).  Early in life, obesity plays a critical role in 
promoting adult onset insulin resistance syndrome, which includes hyperinsulinemia, 
hypertension, hyperlipidemia, type 2 diabetes mellitus, and heightens the risk for 
cardiovascular disease (30).  The implication that childhood obesity is a critical starting 
point to the manifestation of obesity in adults creates an intriguing area of research.  This 
period of rapid growth needs to be better understood and used as a strategy to control 
associated health problems. 
Etiology  
Obesity can be described as an imbalance between caloric intake and energy 
expenditure (13).  Although the mechanisms that promote this imbalance are not 
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completely known, genetics and environment play important roles in the development of 
obesity.  The rise of the obesity epidemic can be partially attributed to unlimited access to 
the convenience of energy dense, highly palatable foods, together with an inactive 
lifestyle (2; 31).  However, evidence for genetic contribution to this epidemic is well 
established from family and twin studies which indicate fat mass is also heritable (32).  A 
number of studies reveal a close relationship between the weight of adopted children and 
their biological parents rather than their adoptive parents, indicating environment is only 
a portion of the equation (33). 
Realistically, obesity has many causes, each of which have variable genetic 
components.  Genes may attribute to 25%-40% of the variability in BMI and contribute 
to differences among individual resting metabolic rate, weight gain in response to over 
consumption, and physical regions of fat storage (34).  Obesity can also be explained by 
rare occurrences, such as single-gene mutations or by various diseases in subjects for 
whom obesity otherwise would not occur (34).  Therefore, some individuals are more 
likely to be predisposed to obesity through their genetic makeup, while others respond to 
a lifestyle which promotes obesity.  Bray has summarized the etiology of obesity: “Genes 
load the guns, the environment pulls the trigger” (34). 
Critical periods and the development of obesity  
Critical periods in growth and development are periods when environmental 
influences alter growth and development with possible lifetime consequences.  Three 
critical periods in development have been identified as influencing early onset childhood 
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obesity and risk for experiencing adulthood obesity (35; 36).  These crucial periods are 
the prenatal and postnatal period, the adiposity rebound period, and adolescence (37). 
Prenatal and postnatal period.   
Gestation is sensitive to environmental effects that can influence the long term 
health, behavior, and function of an individual.  During the first and second trimester of 
pregnancy the hypothalamus begins to develop; availability of metabolic fuels may alter 
development of the hypothalamus and sympathetic nervous system to permanently 
influence the individual’s response to nutrients (38). 
Maximal adipocyte replication occurs during the third trimester.  The availability 
of metabolic fuels and the hormonal environment may influence the number of adipose 
cells that develop during this period and may also influence leptin, insulin, lipoprotein 
lipase, and other key regulatory mechanisms (37). 
Postnatally, infants undergo another critical period, the transition from nursing to 
weaning.  The weaning period is a time of much nutritional significance; the infant shifts 
from dependence on the mother for nutrition to independent control of food intake.  
Moreover, evidence from several species indicates that the mechanisms that activate 
overeating are dormant in early development and then become active around the weaning 
transition, eventually causing increased growth and adiposity (3; 39). 
Animal studies were instrumental in revealing how early nutrition may impact 
growth and development later in life.  One of the first to initiate work of this kind was 
McCance in 1962, when he manipulated litter size such that pups in large litters received 
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less milk than pups in smaller litters (40).  After suckling for a 21 day period, each group 
was weaned and provided unlimited stock diet.  Pups from large litters remained smaller 
than those from the small litters.  Furthermore, the smaller pups from the large litters 
continued to diverge in body size from the larger animals in spite of unlimited food.  This 
early nutrition intervention created a lifelong programming of growth (40).  McCance 
proved that it was the early weeks in postnatal development that promoted this growth 
trajectory, when he conducted the same nutritional manipulation several weeks later for 
three weeks.  Under these circumstances, the animals underfed were smaller, but they 
displayed catch-up growth when re-fed, indicating the period for growth programming 
had passed (41).  Other studies indicated that briefly overfeeding pups from small litters 
during the suckling period induced permanently elevated plasma insulin and cholesterol 
levels in adulthood (42). 
Metabolic programming was demonstrated more recently by feeding neonate pups 
a high carbohydrate milk formula, rather than mother’s milk.  This intervention caused 
substantial changes in pancreatic islet function increasing insulin biosynthesis as well as 
producing alterations in metabolic responses of peripheral tissues, each persisting into 
adulthood.  Pups fed the high carbohydrate diet initially grew at the same rate as pups 
raised by their dams, but during adulthood, they developed obesity even though they 
were fed the same diet as those raised by their dams (43).  Finally, in primates, such as 
female baboons, overfeeding in infancy resulted in the onset of obesity only later in life 
(44).  Evidence from these animal models indicates early events in energy balance 
regulatory systems control metabolic occurrences later in life. 
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There is also evidence for early developmental imprinting in humans.  Near the 
end of World War II, Germany began to restrict food to Northern Holland for over a 6 
month period beginning in October, 1944.  The Dutch famine was a “natural 
experiment,” as individual caloric intake declined from ~1500 calories to ~1000 calories 
per day over a six-month period and was further minimized to ~500 calories per day for 1 
month until the famine ended in May 1945.  Ravelli et al showed that those exposed to 
famine during the last trimester had a reduced prevalence of obesity at 18 years old (45).  
These data suggest leanness later in life may be a result of reduced fat deposition late in 
gestation.  In fact, it is during the last trimester that adipocyte replication and increases in 
body fat become evident (37).  In contrast, individuals exposed to famine during the first 
and second trimester of gestation had a higher incidence of obesity by 18 years of age.  
During the first 2 trimesters, the hypothalamus begins to develop, possibly setting caloric 
cues with the sympathetic nervous system (45). 
Several factors alter interpretation of this experiment, such as lack of data 
pertaining to pregnancy weight gain and birth weight measurements.  It is also reasonable 
to consider those women who carried a fetus to term during famine may have differed 
from those women who experienced miscarriages or failed to become pregnant.  
Regardless, these data provide evidence that occurrences during the gestational period 
may be associated with the prevalence of adiposity later in life (37; 38).  The Dutch 
Famine study revealed early evidence that maternal energy intake even during pregnancy 
can impact the risk of offspring becoming obese later in life (45). 
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Infants of diabetic mothers also show how birth weight can affect adiposity later 
in life.  Gestational diabetes leads to an increase in delivery of glucose to the fetus.  In 
response, the fetus increases insulin production, which increases growth rate and 
development of adipose tissue.  Pima Indian infants exposed to diabetes during gestation 
were more likely to suffer from obesity at birth and later in life than those infants born to 
mothers who were prediabetic or never affected by diabetes (46).  This is not only true 
for the Pima Indians, but also for infants born to diabetic mothers in other populations 
(46).  These infants tend to be larger at birth and are at higher risk for growing up to be 
overweight or obese adults (37; 38; 47).  Animal studies indicate fetal hyperinsulinemia 
can effect and even alter neurotransmitters, eventually leading to the hyperphagia and 
increased body weight in adult offspring (47; 48). 
A number of studies indicate low birth weight is directly linked to the prevalence 
of obesity and subsequently Metabolic Syndrome X later in life (37; 49).  It is important 
to consider that low weight births only account for a small percentage of the general 
population, therefore, low birth weight alone can only contribute minimally to adult 
obesity (50).  
Adiposity rebound.   
Adiposity rebound is a period in a child’s development that may predict increased 
incidence of obesity later in life.  First described by Roland, this period captures BMI 
increasing during infancy, then declining to nadir levels between 6 to 8 years of age, and 
then beginning to increase with age thereafter (36).  Children who undergo an earlier 
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rebound period may, in fact, be at greater risk for being overweight or obese later in life 
(18; 51; 52).  For example, the Fels Longitudinal Study recorded numerous 
measurements of 338 individuals until 25 years of age; 159 of the subjects were studied 
from 35 to 45 years of age.  The data indicated that those with earlier adiposity rebound 
showed maximum BMI at an earlier age and a higher BMI when maximum BMI was 
achieved (18; 53).  Therefore, this period appears to partially predict adult weight status. 
Other mechanisms are likely to contribute to this early effect.  During this period, 
early childhood behaviors associated with food intake and activity begin to be 
recognized.  Maternal regulation of food plays a central role in the capability of the child 
to regulate food later in life.  Those children living in strictly regulated environments are 
susceptible to impaired self-regulation of food and increased risk for adiposity (54).  
Early adiposity rebound may also be related to infant exposure to gestational diabetes 
(37), while other research indicates early maturation can be correlated to increased levels 
of adiposity (23; 37; 55).  
The age of adiposity rebound may reflect a period of altered genetic 
programming, inherited susceptibility to obesity, and/or modifiable environment 
influences (38).  It is important to recognize that adiposity rebound is based on a number 
of population studies defining BMI as the primary marker for adiposity.  Because BMI is 
a measure of weight divided by height squared,  without other anthropometric measures, 
it is not completely clear whether BMI reflects increased weight (50).  Nevertheless, if 
BMI does reflect increased weight, other measures are needed to determine if such 
weight is a result of body fat rather than increased bone or muscle mass.  The time of 
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adiposity rebound does appear to be a critical time development, yet biological and 
behavior determinants as well as secondary anthropometric measurements should be 
evaluated more closely to determine if adiposity rebound is a modifiable risk factor for 
adult obesity which could be prevented and treated (52). 
Adolescence.   
Adolescence is a third critical period in childhood.  Evidence shows the older a 
child is when becoming at risk of overweight or overweight, the greater the risk that the 
overweight will persist into adulthood (18; 22).  It is predicted that 25-50% of overweight 
adolescents grow up as obese adults.  In fact, obese adolescents are 2 to 11 times more 
likely to become obese adults than non-obese adolescents (22). 
Overall, the studies conducted in this area indicate childhood obesity is often 
likely to persist into adulthood.  However, the criteria for obesity can vary between 
studies as well as the statistical interpretation and the time interval studied from 
childhood to adulthood.  Guo et al  showed in a long-term prospective study that 18 year 
old adolescents at ≥95th percentile BMI were at significantly higher risk for overweight 
by 35 years of age (35).  The probability for adult overweight was 78% for male and 66% 
for female adolescents.  Similar findings from a 1958 British birth cohort suggest the 
persistence of obesity into adulthood is similar in males and females.  Data indicates at 33 
years of age 17% of males and 18% of females were >95th percentile BMI at 7 years of 
age (22).  However, other findings suggest that gender may affect the persistence of 
obesity into adulthood.  A follow-up of the National Survey of Health and Development 
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examined males and females who were obese by 36 years of age, using an internal 
criteria for overweight as >130% of BMI.  This study found 11% of men and 24% of 
women were obese at 20 years of age, yet at 14 years of age, 14% of males and 32% of 
females were considered obese (56).  One of the most extensive studies was conducted 
over a 55 year span, tracking 181 subjects in the Harvard Growth Study from adolescence 
to old age (57).  Individuals in the study were considered overweight as adolescents with 
>75th percentile BMI for at least two years.  Results indicated male participants who were 
overweight during adolescence suffered from increased risk of mortality from all causes 
and disease-specific mortality, yet women did not.  However, risk of morbidity from 
coronary heart disease and atherosclerosis was increased in both sexes who had been 
overweight as children.  Data suggested that being an overweight adolescent is a more 
accurate predictor of these risks later in life than being overweight in adulthood (57). 
Genetic and Biological Determinants of Obesity   
In the last several years, 7 human genes and more than 20 mouse genes have been 
associated with fat mass accumulation (2).  Rodent research provides valuable insights 
into energy balance that are often relevant to humans.  Table 1 provides a summary of 
some of the genes that influence fat mass in humans and mice.  Although rare, several 
human disorders of energy balance can be attributed to genetic mutations that produce 
morbid obesity in childhood.  Such genetic diseases include Prader-Willi Syndrome, 
Cohen’s Syndrome and Bardet-Biedl Syndrome.  
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Table 1.  Genetic mutations in humans and mice 
Gene Name Will the genetic mutation 
cause human obesity? 
Will the genetic mutation 
cause increased fat mass in 
mice? 
Leptin Yes, rare Yes 
Leptin receptor (central and 
peripheral) 
Yes, very rare Yes 
Melanocortin receptor-4 
(MC4R) 
Yes, 3%-5% of morbidly 
obese 
Yes  
α-melanocyte stimulating 
hormone (α-MSH) 
Yes, very rare, red hair, and 
obesity  
Yes 
Prohormone convertase-1 
(PC1) 
Yes, one known case Yes 
Bardet-Biedl Yes, very rare Unknown 
Dunnigan partial 
lipodystrophy  
Yes, rare Unknown 
Agouti gene-related protein 
(Agrp) 
Unknown  Yes 
Tubby (TULP1) Unknown Yes 
 
Prader-Willi Syndrome 
Prader-Willi syndrome (PWS) is caused by genetic mutations in a region of 
chromosome 15 that is subject to genomic imprinting (58).  Genomic imprinting during 
gametogenesis suppresses expression of maternal alleles of genes in this region.  This 
means that only paternally inherited alleles are expressed in normal development.   
Many Prader-Willi children inherit chromosomal deletions from their fathers that 
eliminate the paternally derived alleles, leaving only the silenced maternal alleles in the 
genome (59).  Others develop Prader-Willi Syndrome because of maternal uniparental 
disomies, in which both copies of chromosome 15 are inherited maternally and none are 
  17
inherited paternally.  In both cases, it is the loss of paternal alleles that determines the 
phenotype. 
The Prader-Willi Syndrome phenotype severely affects appetite and feeding in 
infancy and childhood (60).  Prader-Willi Syndrome infants have minimal appetite and 
often have such difficulty suckling as infants that they require nutritional support.  A 
marked change occurs during the first year or two of life.  Appetite and feeding ability 
improve so much that these infants develop hyperphagia. The onset of hyperphagia 
initially produces an improvement in growth, but because hyperphagia never resolves, it 
rapidly leads to the development of obesity.  This developmental pattern suggests that the 
pathways that mediate hyperphagia are not fully developed in infants, but become 
activated during the first two years of life.  
These symptoms have been attributed to hypothalamic dysfunction and decreased 
energy utilization (61-63).  These dysfunctions have lead some researchers to hypothesize 
this syndrome produces a perception of starvation in hypothalamic feeding centers (62).  
Individuals with Prader-Willi syndrome, produce normal increased levels of 
cholecystokinin and leptin after food intake (62; 64).  They also have reduced levels of 
orexigenic agents, such as neuropeptide Y and agouti-related protein in the 
hypothalamus, similar to other obese individuals (61; 62).  Under normal conditions, such 
levels of cholecystokinin, leptin, neuropeptide Y, and agouti-related protein are 
associated with satiety, but in Prader-Willi Syndrome hyperphagia exists despite the 
metabolic and physiological consequences of such peripheral factors controlled by the 
hypothalamus (62).  Therefore, it appears there is an alteration in the pathways controlled 
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by the hypothalamus that allows the body to incorrectly act as if in a state of starvation.  
Not only is appetite enhanced, but metabolic rate is low, and gonadotropin release is 
impaired as in other states of starvation.  
Proopiomelanocortin C (POMC) 
Proopiomelanocortin (POMC) is a single gene product that is spliced into several 
different peptides, including α-melanocyte–stimulating hormone (α-MSH).  POMC is 
produced in the arcuate nucleus in the hypothalamus and acts to integrate hormonal 
signals from adipose cells.  The activation of POMC increases α-MSH, which binds to 
melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R). 
A mutation in POMC identified in humans affects hair color, skin color, food 
intake, and energy expenditure due to its inactivation in the hypothalamus.  The first 
known case was documented in 1998 by Krude et al, revealing a red haired, fair skinned 
girl who had a normal birth weight, and developed cholestasis at 3 weeks of age (65).  
Because her older brother had died at 7 months of age and was diagnosed postmortem 
with adrenal insufficiency which caused hepatic failure and severe cholestasis, this girl 
was diagnosed with adrenocorticotropin (ACTH) deficiency at 23 days of age.  She was 
successfully treated and the cholestasis resolved.  She grew normally during the first 3 
months of life, but by 4 months of age, the child’s parents noticed a substantial increase 
in appetite, which produced early-onset obesity.  The large weight gain during this short 
period prevented the patient from walking until 2 years of age, even though mental 
development appeared to be normal (65). 
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Approximately seven other such cases have been reported worldwide.  Although 
rare, these cases emphasize the importance of POMC in energy homeostasis indicating 
variants in POMC may be a contributing factor to the common form of early-onset 
obesity (65; 66).  Like children with Prader-Willi Syndrome, the pathways for 
hyperphagia appear to have been inactive during infancy in the girl with a POMC 
mutation, and emerged later in early development. 
Rodent Models 
Parabiosis studies 
Early parabiosis studies, which involve the surgical union of two animals to 
produce a cross-circulation of blood exchange, have assisted in revealing the metabolic 
role of hormones.  Using rats, Hervey showed when one parabiotic partner was given 
lesions to the ventromedial hypothalamus that caused the rat to overeat and become 
obese, the non-lesioned parabiotic partner reduced its food intake and its adipose mass 
(67).  Hervey proposed that a circulating satiety factor produced by the expanding fat 
mass of the lesioned rat was responsible for inhibition of food intake in the parabiotic 
partner.  He proposed that the hypothalamic lesions prevented the rat from responding to 
the elevated circulating satiety factor.  In fact, he hypothesized the elevated satiety factor 
in the obese rat produced effects to decrease food intake in the lean parabiotic partner 
without lesions, causing death by starvation.  
Others extended these parabiosis studies to genetic models of obesity: obese (ob), 
diabetes (db), and fatty (fa) (68-70).  These mutations are characterized by hyperphagia, 
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decreased energy expenditure and early-onset obesity.  Coleman demonstrated when 
obese db/db mice are parabiosed to wildtype mice, the db/db is unaffected by the union, 
while the wildtype lost significant weight, experienced hypoglycemia, and eventually 
died (68).  When ob/ob mice were parabiosed to their lean littermates, the obese animals 
did not experience rapid weight gain and in fact consumed less food but did not die (69).  
When the db/db and ob/ob were parabiosed, the ob/ob partner experienced weight loss, 
became hypoglycemic, and also died of starvation.  Coleman suggested that the ob locus 
served as a humoral satiety factor, whereas the db locus functioned to produce a molecule 
or receptor to respond to this satiety factor (69). 
Harris et al also demonstrated similar findings to those of Coleman’s in the db/db 
mice, when performing parabiosis between fatty (fa/fa) and lean Zucker rats (70).  The 
lean parabiotic partner of the fatty rats reduced its food intake and its adipose mass.  
Thus, fatty rats appeared to produce the humoral factor but failed to respond to the 
circulatory satiety factor. 
Leptin and leptin receptors 
The conclusions of Coleman’s parabiosis studies were confirmed later with the 
cloning of ob and db.  The ob/ob mouse inherits an autosomal recessive allele that 
increases energy efficiency and food intake, leading to early onset obesity, with the ob/ob 
mouse eventually tripling the weight of a normal mouse.  The development of obesity in 
ob/ob mice is accompanied by fasting hyperglycemia, hyperinsulinemia, infertility, 
thyroid dysfunction, and stunted linear growth.  The cloning of ob mutation by Zhang et 
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al in 1994 began a series of important discoveries in the molecular basis of energy 
balance (71).  The ob gene was shown to encode a secreted protein, subsequently named 
leptin.  Leptin is produced predominately by adipose tissue, released in the bloodstream, 
and detected by leptin receptors in the hypothalamus, as well as many other tissues.  
Exogenous leptin injected intracerebroventricularly suppresses food intake and increases 
energy expenditure in ob/ob mice, restoring body weight to normal levels (72).  Most 
obese individuals are characterized by elevated circulating leptin, which correlates with 
adipose tissue mass.  Although there are a few documented cases of individuals with 
congenital leptin deficiency who can be successfully treated with recombinant leptin, 
most of the obese population are resistant to the weight reducing effects of recombinant 
leptin (73; 74). 
The db/db mouse is strikingly similar to the ob/ob mouse.  It also inherits fasting 
hyperglycemia, hyperinsulinemia, infertility, thyroid dysfunction, and stunted linear 
growth.  But the abnormalities found in the db/db mouse model are caused by a mutation 
in a leptin receptor splice variant predominantly expressed in the hypothalamus (75; 76).  
This splice variant causes the intracellular signaling domain of the leptin receptor splice 
variant to be defective, so that leptin signaling cannot be activated despite high 
circulating leptin levels (75; 77).  Obesity in the db/db mouse cannot be resolved with 
administration of recombinant leptin (72).  Thus, leptin and its receptors serve in a 
feedback loop to regulate fat mass. 
There are several documented cases of children who fail to produce leptin because 
of genetic mutations in the human homologue of the ob gene.  These children have 
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normal birth weight, but develop severe early-onset obesity.  Like ob/ob mice, these 
individuals can be treated using recombinant leptin; decreasing hyperphagia and fat mass 
(2).  Even with treatment of recombinant leptin, these children are above the 95th 
percentile for normal weight and age.  Furthermore, they experience recurring episodes of 
increased hyperphagia during leptin therapy as the dose of leptin becomes ineffective. As 
a result, leptin dosages must be elevated when such episodes occur and these symptoms 
will then resolve temporarily (31; 78).  In these children, leptin primarily affects food 
intake, and has no detectable effect on energy expenditure (31; 78).  This suggests that 
leptin plays less of a role in regulating energy expenditure in humans than it does in mice. 
Although leptin decreases fat mass in leptin deficient mice and humans, it is not 
as effective in humans and animals that have normal leptin expression.  An increase in 
adipose mass normally leads to an increase in leptin levels.  Although obese individuals 
tend to produce high levels of leptin, it appears they are resistant to its actions. 
There is also evidence that responses to leptin change developmentally.  Even 
though fat mass is relatively low during the first few days of life, there is a developmental 
surge in leptin levels (39).  During the neonatal period, the physiological growth 
requirements, such as maximal food intake and maintenance of high metabolic rate for 
survival, appear to contradict the known role of leptin.  Mistry et al observed the 
developmental progression of leptin’s ability to alter food intake and energy expenditure 
early in life; leptin accelerates metabolic rate in lean and ob/ob mice early in life, but 
does not affect food intake until the fourth week of life (39).  This provides evidence that 
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the leptin signaling pathways regulating hyperphagia are inactive during the neonatal 
period but are activated at a specific developmental age. 
Lipodystrophy  
Lipodystrophy syndromes are also characterized by low leptin levels (79).  
Lipodystrophy refers to a heterogeneous group of conditions classified as acquired or 
genetic, describing both partial and complete loss of subcutaneous adipose tissue at birth 
or later in life (80).  The extent of fat loss in these patients defines the severity of their 
metabolic complications.  Despite variations in fat loss and different etiologies pertaining 
to each type of lipodystrophy, these patients often share common metabolic abnormalities 
in varying degrees, such as insulin resistance, glucose intolerance or hyperglycemia, and 
hypertriglyceridemia (79).  As a result of minimal adipose mass, there is a deficiency in 
leptin signaling, thought to contribute to many of the metabolic abnormalities 
characterized by lipodystrophy (81-83).   
Patients diagnosed with localized lipodystrophy suffer from cosmetic 
abnormalities where fat loss is selective to various parts of the body, creating depressions 
and indentations subcutaneously.  In contrast, patients with congenital generalized 
lipodystrophy suffer from nearly complete absence of adipose mass and adipocyte-
derived hormones, such as leptin, causing severe hyperphagia early in life (84).  Unger 
RH et al suggest that leptin functions regulate intracellular homeostasis of fatty acids and 
triglycerides in nonadipocytes, such as the muscle, liver, and pancreas, but prevent fatty 
acid overload (85).  When leptin production is minimal, lipotoxicity occurs in 
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nonadipocytes due to ectoptic lipid accumulation (86; 87).  These physiological 
occurrences lead to severe metabolic complications, such as hypertriglyceridemia, severe 
insulin resistance, diabetes, hepatic steatosis, and cardiac complications (88-90). 
Over the last decade, advances have been made to understand the mechanism 
underlying this disease and why adipose tissue is vital in the prevention of metabolic 
abnormalities.  One hypothesis is that leptin is a critical determinant in the prevention of 
insulin resistance and hypertriglyceridemia seen in lipodystrophy.  The administration of 
recombinant leptin to lipodystrophic humans and rodents dramatically improves glucose 
and lipid abnormalities associated with this condition including insulin resistance, 
hypertriglyceridemia, and hepatic steatosis (82; 91; 92).  Others suggest that the 
metabolic abnormalities are a result of problems in the differentiation of adipocytes (79).  
During adipogenesis, precursor cells undergo transient expression of transcription factors, 
thus becoming preadipocytes.  Preadipocytes develop the ability to store triglycerides 
through the activation of multiple genes controlled by key transcription factors such as 
peroxisome proliferator-activated receptor gamma (PPARγ).  Transcription factors, such 
as sterol regulatory element-binding proteins (SREBP-1)/adipocyte determination- and 
differentiation-dependent factor 1 (ADD-1), are also involved in activating key factors or 
controlling synthesis of their ligands.  Defects during vital differentiation periods may 
lead to adipocyte deficiency.  Evidence indicates that thiazolidinediones (TZDs), oral 
hypoglycemic agents, classified as agonists for PPARγ, stimulate adipocyte 
differentiation in vitro and increase insulin sensitivity in vivo (6; 93).  Therefore, 
thiazolidinedione compounds appear to be a favorable treatment in alleviating the 
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metabolic abnormalities found in lipodystrophy syndromes.  When troglitazone, a 
member of this class of drugs, was given to rodents with lipodystrophy syndromes, the 
effects were positive, improving metabolic condition and increasing adipose mass (94).  
Human treatments also provide similar results.  Lipodystrophic patients treated with 
troglitazone for 6 months showed improvement in metabolic control, with decreased 
hemoglobin A1c, triglyceride levels, and free fatty acids levels.  Furthermore, patients 
experienced a 3% increase in subcutaneous adipose tissue over the treatment period (95).  
These findings suggest TZDs stimulate adipocyte differentiation and possibly promote 
normal metabolic function, alleviating glycosuria and sparing of fat stores in this 
population.  Nevertheless, more human trials are still needed over a longer period of time, 
using not only troglitazone but more recent classes of TZDs, such as rosiglitazone and 
pioglitazone.  Such studies would be helpful in further evaluating the benefits as well as 
the potential risks involved. 
Many of the metabolic complications characteristic of lipodystrophy are similar to 
a cluster of metabolic abnormalities faced by obese individuals collectively known as 
“metabolic syndrome X” or “insulin resistance syndrome,” characterized by glucose 
intolerance, noninsulin-dependent diabetes mellitus (NIDDM), dyslipidemia, and 
hypertension (96; 97).  As a result of these similarities, genetic lipodystrophy defines an 
extreme example of monogenic insulin resistance, providing a research model to study 
the underlying mechanism of insulin resistance associated with the obese phenotype.  
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Melanocortin pathway 
Leptin is produced by the peripheral adipose tissue and acts on the arcuate 
nucleus in the hypothalamus to activate proopiomelanocortin C (POMC) (66).  POMC is 
a single gene product that is spliced into several different peptides, including α-
melanocyte–stimulating hormone (α-MSH).  The activation of POMC increases α-
melanocyte–stimulating hormone (α-MSH), which binds to melanocortin-3 and 
melanocortin-4 receptors (MC3R and MC4R). 
The discovery of the melanocortin pathway, as it relates to food intake and energy 
expenditure, began in a mouse strain known as agouti yellow mice.  These mice inherit a 
dominant mutation that causes obesity and yellow coat color.  The mutation causes 
ectopic expression of a protein called agouti or agouti signaling protein (ASIP), which is 
normally expressed only in the skin (2; 98).  When agouti protein is expressed in the 
hypothalamus, it blocks binding of α-MSH to MC3R and MC4R.  Each of these receptors 
is expressed in the centers of the hypothalamus that regulate weight.  Although only the 
MC4R mutations cause increased food intake and decreased energy expenditure in 
humans, reports indicate MC3R may also be associated with obesity but more research is 
needed.  In fact, mutations in MC4R accounts for nearly 4% of all common cases of 
human obesity (2; 99). 
The Zucker fatty (fa/fa) Rat 
The Zucker fatty (fa/fa) rat inherits an autosomal recessive mutation that causes 
early onset obesity (100).  The fatty phenotype includes increased energy efficiency, 
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hyperphagia and infertility.  As fatties become obese they also develop hyperlipidemia, 
insulin resistance, renal disease, and other pathologies.  Female fatties are essentially 
sterile, displaying a small, underdeveloped uterus, while males are classified are infertile 
because they are occasionally able to breed.  As a result, heterozygote Zucker rats are the 
most appropriate breeders to maintain a colony (100). 
The fa mutation was mapped to rat chromosome 5, in a region that shares synteny 
homology with the region of mouse chromosome 4 that contains the db mutation (101).  
This suggested that fa and db affect rat and mouse homologs of the same gene.  This was 
confirmed after the db mutation was cloned and shown to be a leptin receptor (102; 103). 
The fatty rat inherits an amino acid substitution at position 269 of the leptin 
receptor protein sequence, changing glutamine to proline within the extracellular domain 
of the leptin receptor, causing a disruption in leptin signaling (104).  There are six splice 
variants of the leptin receptor in the rat, and the fa is incorporated into all the splice 
variants (105).  This differs from the db mutation, which affects the intracellular 
signaling domain of only one leptin receptor splice variant, the B form (102).  As a result, 
the fatty rat leptin receptor has a reduced ability to respond to leptin, although large doses 
of leptin can stimulate some signaling through the mutant receptor (104). 
In the initial description of the fatty mutation, it was noted that fatties became 
visibly obese after weaning, and also developed elevated amounts of a “white, milky 
substance” in serum samples at this age (100).  This substance was found to be 
circulating lipids (106).  This observation provided the first clue that a developmental 
program was involved in the onset of obesity in fatties. 
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Thermogenesis  
Preobese suckling fatties accumulate excess adipose mass by maintaining a lower 
body temperature than their lean littermates, even when food intake is similar (107).  
They remain visibly indistinguishable from their lean littermates until the fourth week of 
life (107; 108).  When fatties and lean pups are reared in a neutral thermal environment, 
both genotypes accumulate the same amount of adipose mass (109).  This demonstrates 
that energy expenditure produces the difference in adipose mass between the fatty and 
lean pups with similar energy intakes.  These data suggest that a portion of the leptin 
signal transduction pathway affecting energy expenditure functions normally during the 
neonatal period in normal rats, but is defective in fatties (107; 108; 110).   
During the early developmental period, a reduction in sympathetic activity 
controlling thermogenesis in brown adipose tissue appears in the fatty rat, which partly 
contributes to the etiology of genetic obesity in fatties (108).  Brown adipose tissue 
develops early in embryonic development, functioning to primarily dissipate energy in 
the form of heat during adaptive non-shivering thermogenesis through activation of the 
mitochondrial β-oxidative pathway by uncoupling proteins (111; 112).  When this system 
is suppressed or ablation of brown adipose tissue in rodent models occurs, there is an 
increase metabolic efficiency, resulting in obesity (113). 
Weaning practices  
Many of the metabolic abnormalities associated with altered energy balance in 
the Zucker fatty rat emerge during or immediately following the weaning period.  During 
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this period that fatty rats becomes distinguishable from their lean littermates becoming 
visibly obese and displaying defects in glucose homeostasis (114).  In this context, 
weaning is defined as a common husbandry practice of separating the pups from their 
dam at 3 weeks of age.  This unnatural procedure promotes abrupt alterations in diet and 
thermal environment (115; 116).  When pups remain with the dam, weaning is gradual 
and nursing can continue for up to 5 weeks of age (116). 
It should be noted that early separation of pups from the dam promotes stress 
responses that alter the timing of developmental events (115; 116).  When maternal 
separation precedes such events, it is difficult to differentiate between those that are 
stress-induced and those that are a result of spontaneous developmental occurrences 
(115).  Several observations indicate that, when animals are weaned suddenly, weight 
gain is stimulated in the fatty rat by maternal separation rather than natural 
developmental occurrences (3; 115).  In fact, enzymatic activity appears to be impacted 
by weaning practices, whether this is a minute delay in maturation or an effect that is not 
detected until later in development weaning appears to be a contributing factor.  Such 
enzymes include jejunal sucrase, hepatic glucokinase, pancreatic amylase, lipase, and 
chymotrypsin (115). 
Weaning research provides evidence that developmental occurrences are affected 
by alterations in diet although diet is not the only initiator of the ontogenic changes.  
Such effects are demonstrated when pups that remain unweaned are compared to those 
that are weaned according to traditional practices.  Initially, both groups display similar 
levels of jejunal sucrase activity, verifying these levels are not initiated by dietary 
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practices.  With age, both groups diverge, indicating this early cue produces changes that 
eventually occur later in life (115). 
Physical activity levels are also altered by the timing of weaning which may 
contribute to the early onset obesity seen in fatties.  Moreover, the fatty does not appear 
to be born less active than lean littermates; rather inactivity appears to coincide with 
separation from the dam at early weaning.  Although activity levels decline in fatties 
when unnatural weaning does not occur, this time point is much later in development and 
is also associated with a period in which the dam spontaneously weans pups (117). 
It is evident that separating these developmental occurrences from stress 
responses is difficult especially when weaning precedes a defining developmental 
occurrence (3; 117).  Studies by Truett et al revealed when maternal separation was no 
longer a limiting factor and pups were left with their dams up to 4 weeks of age, a 
reduction in the variation of growth with age occurred.  Under these natural conditions, 
fatties suddenly developed robust hyperphagia after 22 days of age and rapidly developed 
overt obesity soon after.  Because pups were not weaned this developmental 
physiological event appears to be independent of environmental factors induced by 
maternal separation (3). 
Hyperphagia  
The onset of hyperphagia in the Zucker fatty rat is an area that has been explored 
by several researchers using a variety of experimental techniques.  Although several 
hypotheses have been proposed, the precise timing of this developmental occurrence 
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remains unknown due to inconsistent findings between investigators and different 
methodologies. 
The portion of the leptin signal transduction pathway that suppresses energy 
intake in adulthood appears to be insignificant in neonate pups when maximal food intake 
is needed to support growth during this critical period (118).  Exogenous leptin during the 
neonatal period in mice does not promote the anorectic effects seen later (39).  In fact, the 
neonatal period may not be a time when animals are insensitive to leptin, but rather leptin 
appears to produce a developmental signal that assists in the formation hypothalamic 
circuitry pathways that maintain leptin signals to the brain later in life to mediate food 
consumption (119). 
Several studies have demonstrated fatty and lean littermates consume approximately 
the same amount of milk during the suckling period (120; 121).  Others have found that 
even after injection of leptin into wildtypes, energy intake remains unaffected during this 
critical period of growth and development (122). 
Kowalski et al demonstrated a technique to determine the onset of hyperphagia by 
capturing ingestion practices of preweaned fatties independent of the dam.  To stimulate 
feeding, pups were removed from the dam and placed in an incubator for 3.5 hours with 
only littermates.  After fasting the animals and eliminating urine and fecal matter, pups 
were provided ad libitum access to half and half (milk and cream) for 20 minutes.  
Afterwards, animals were weighed to estimate food intake at 4 ages.  Using this 
environment, fatty pups ate significantly more than lean pups at 12, 15, and 18 days of 
age (123). 
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Others have also concluded fatties experience hyperphagia early in development.  
McLaughlin and Baile observed food intake by training pups to release food pellets by 
pressing a bar, at which time several parameters were recorded for analyzed (124).  Data 
indicated there was an elevation in food intake at 3 weeks of age due to increased meal 
frequency, which continued to be elevated by 4 weeks of age due to meal duration.  
Researchers did not specify the weaning or rearing practices used, but it is unlikely that at 
3 weeks fatties were visibly obese; therefore, it is possible these animals were older 
(124). 
Evidence also exists that fatty pups consume similar amounts of food as their lean 
littermates in early development, and the onset of hyperphagia does not become apparent 
until later in life (121).  Buchberger and Schmidt demonstrated that 5 and 15 day old fatty 
and lean littermates raised in a thermoneutral environment and exposed to an abundant 
supply  of milk for 1 hour, in fact, consumed similar amounts of milk based on body 
weight (121). 
Together these observations offer evidence to suggest a developmental occurrence 
appears in early life that may alter the onset of hyperphagia, yet it is difficult assess 
realistic consumption levels of fatties.  Each of the studies described creates an extremely 
unnatural environment that may induce a stress response, altering developmental timing.  
Truett et al demonstrated that changes in daily weight gains, stomach contents, liver 
weight, and plasma insulin are significantly increased at 22 days, when pups are reared in 
a natural, unaltered environment (3).  Therefore, these findings provide evidence that the 
onset of hyperphagia occurs during the fourth week of life (3).  
  33
Diet composition  
Transitioning from total dependence on the dam to independent control of food 
begins to take place during the third week of life.  During this time, pups begin 
consuming chow, introducing carbohydrates as the primary macronutrient source rather 
than fat found in milk.  Several have observed how this dietary modification alters 
hyperphagia.  Vaselli and Maggio reviewed the course of hyperphagia when placing 
juvenile fatty rats on a high fat diet and found hyperphagia increased and there was an 
accelerated accumulation of adipose mass (125). 
In contrast, others have compared the effect of weaning 16 day old fatties onto a 
diet similar in macronutrient content to the dam’s milk versus a diet high in 
carbohydrates similar to chow.  This study found those animals weaned onto the high fat 
diet were less obese than those fed the high carbohydrate diet (126).  These studies 
provide contradicting results, failing to define the onset of hyperphagia as it relates to diet 
composition and inducing unnatural environmental practices when performing early 
weaning.  
Lipid and Glucose Metabolism  
Physiological Role of Adipose Tissue 
Adipose tissue is a specialized tissue in the human body forming in areas with 
dense connective tissues, including the subcutaneous layers between the muscle and the 
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dermis, in addition to areas encompassing the heart, kidneys, and other internal organs.  
Fat cell development usually occurs in clusters and disperses in many sites of the body.  
Adipose tissue is found in two forms within the body - white adipose tissue and 
brown adipose tissue (111).  White adipose tissue serves to provide heat insulation, 
mechanical cushion, and most importantly is a source of energy. These unilocular cells 
appear as a single large lipid droplet, which pushes the cell nucleus against the plasma 
membrane.  
Brown adipose tissue acts to dissipate heat rather than store it, essentially 
defending against cold and protecting against obesity.  Therefore, heat production is used 
for non-shivering thermogenesis and for utilization of excess caloric intake via diet-
induced-thermogenesis.  The mechanism of heat generation occurs in the mitochondria of 
brown adipose tissue which has a specific carrier called uncoupling protein that transfers 
protons from outside to inside without further production of ATP tissue.  Brown adipose 
tissue has a multilocular phenotype, containing many smaller lipid droplets.  The brown 
color of this tissue is a result of cells' rich vascularization and densely packed 
mitochondria (111; 127). 
Adipose tissue is comprised of triglycerides stored in the cytoplasm as lipid 
droplets constructing the adipocyte.  Triglycerides are synthesized through circulating 
lipoproteins or de novo lipogenesis.  In fact, triglycerides are constantly being 
synthesized and broken down in the adipose tissue due their short half-life.  De novo 
lipogenesis is the metabolic process in which glucose is converted to triacylglycerols 
(TAG) when energy demands have been met; whereas, when energy levels are low, TAG 
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undergo a metabolic process called lipolysis to release fatty acids for energy demands 
(111; 127). 
Many modern molecular advances have further defined adipose tissue not only as 
a storage unit for energy but also as an important component in the secretion of gene 
products or acting as a signaling molecule.  These research efforts clearly define adipose 
tissue as a primary link to metabolic programming (111; 112). 
De novo lipogenesis 
De novo lipogenesis is an important metabolic process that allows the body to 
store calories efficiently in the form of fat.  This process is essential during periods of 
dietary restriction, allowing for survival.  The metabolic process is summarized as 
follows (128).  Lipogenesis begins when glucose is ingested and converted through 
glycolysis to pyruvate.  Pyruvate is oxidized by pyruvate dehydrogenase to produce 
acetyl-CoA which is then converted to citrate by citrate synthase.  At this point, citrate 
can be oxidized by the TCA cycle to produce energy, or it can be exported from 
mitochondria to the cytosol, where it is converted back to acetyl-CoA by citrate lyase. 
Acetyl-CoA is converted malonyl-CoA by acetyl-CoA carboxylase (ACC).  ACC is a 
rate- limiting step in fatty acid synthesis.  Palmitate is synthesized from acetyl-CoA and 
malonyl CoA using the catalytic properties of fatty acid synthase (FAS) and nicotinamide 
adenine dinucleotide phosphate (NADPH) as the reducing equivalent.  The NADPH 
required for the activity of FAS is derived from converting malate to pyruvate by malic 
enzyme or by the enzymes involved in the pentose phosphate shunt.  De novo lipogenesis 
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is a functioning pathway as a result of ACC and FAS.  ACC functions as the short-term 
rate limiting step in the regulation of fatty acids and FAS is the long-term rate limiting 
step in this process (129).  
Fatty acids are ingested in the diet primarily as triglycerides or synthesized by the 
liver.  Triglycerides are comprised of three long chain fatty acids attached to a glycerol 
backbone.  They are carried from the intestines in chylomicrons or from the liver in very 
low density lipoproteins (VLDL).  Lipoprotein lipase (LPL) in peripheral tissues 
hydrolyzes triglycerides to glycerol and free fatty acids.  Lipoprotein lipase is synthesized 
in adipocytes and secreted into adjacent endothelial cells.  Chylomicrons and lipoproteins 
(very low density lipoproteins) contain an apoprotein, which activates LPL allowing free 
fatty acids to be taken up by adipocytes.  When inside the adipocyte, fatty acids become 
part of a pool that is constantly being replaced.  Before the fatty acids can be stored in the 
adipose tissue, they must first combine with coenzyme A to form a thioester and then 
they are re-esterified to glycerol to form triglycerides.  Glucose provides the majority of 
glycerol for this re-esterification process (127; 129). 
Insulin also has multiple roles in the lipogenic process.  Insulin stimulates LPL 
formation, allowing circulating triglycerides to be hydrolyzed and free fatty acids to enter 
the adipocyte.  Insulin is also required for the transport of glucose, which is a primary 
component of the re-esterification of the triglycerides once inside the adipocyte.  Lastly, 
insulin activates several enzymes that promote the conversion of glucose to fatty acids 
(127; 129). 
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Fatty acid synthase (FAS) 
As previously explained, FAS is an essential component of de novo lipogenesis.  
Biosynthesis of fatty acids in simple life forms such as bacteria perform these steps by 
catalyzing separate peptides, whereas higher life forms such as mammals have 
consolidated these multiple steps into a single protein produced by a single gene.  FAS is 
a homodimer with each identical peptide subunit being approximately 260 kDa in size 
(130).  Each subunit contains 8 functional domains, 6 of which are required for synthesis 
and elongation of the fatty acid chain (129; 130). 
Nutritional and hormonal regulation 
Alterations in diet composition promote fluctuations in FAS expression. 
Carbohydrates are a key regulating factor of FAS expression in the animal model (131).  
In Zucker rats, FAS mRNA concentrations are low during the suckling period and 
dramatically increase when weaned onto a high carbohydrate diet, with fatties expressing 
the highest levels.  Yet, when pups are weaned onto a high-fat diet these changes 
preclude this increase (8; 132).  Others have shown there is also a fasting and refeeding 
response.  When animals are fasted for a period of time and then refed a carbohydrate 
diet, hepatic FAS protein levels will increase (131).  Feeding animals a diet consisting of 
polyunsaturated fatty acids will also decrease FAS expression at the level of gene 
transcription.  This inhibitory effect of FAS by dietary fatty acids has not been observed 
with saturated or monounsaturated fatty acids (133). 
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Sterols also have properties that regulate gene expression of FAS.  Sterols interact 
with sterol regulatory element-binding proteins (SREBP-1 and SREBP-2).  FAS contains 
2 SREBP-1 binding sites activating transcription of this enzyme (134).  Like FAS, 
SREBP-1 is also decreased by fasting and induced when refeeding a high carbohydrate 
diet, indicating SREBP-1 may mediate insulin’s stimulatory effects of FAS during these 
periods (135).  Hormones also play a crucial role in FAS expression.  It is during fasting 
and refeeding of high carbohydrate diets that insulin levels will increase and glucagon 
will decrease causing FAS mRNA induction to be stimulated.  When animals are insulin 
deficient, such as diabetic mice, FAS mRNA levels will fall, yet this effect can be 
reversed when injecting these animals with insulin (136).  It appears activation of FAS by 
insulin mediation is a result of a insulin response element (IRE) found on the FAS 
promoter (137; 138).  Yet when glucagon or dibutyryl cAMP is administered, FAS 
expression is suppressed (136).   Thus, it appears glucagon acts through cAMP-dependent 
mechanisms to decrease synthesis of FAS (136). 
Thyroid hormone (T3) also increases FAS expression in adipocytes through gene 
transcription (137).  Hyperthyroid rats show FAS mRNA levels are increased 9- fold in 
the liver and 3- fold in the white adipose tissue in comparison to hypothyroid rats (139). 
Transcriptional regulation of adipose differentiation  
Peroxisome proliferator-activated receptors (PPARs)  
Peroxisome proliferator-activated receptors (PPARs) are members of a subfamily 
of nuclear hormone receptors which contain type II zinc finger DNA binding motif (140).  
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Such ligand-activated nuclear receptors are pivotal components of gene transcription and 
intracellular function in a diverse number of biological functions, including lipid and 
glucose homeostasis, cellular proliferation, and differentiation (141).  As shown in Figure 
1, the PPAR subfamily form heterodimers with another nuclear hormone receptor, 
retinoid X receptor (RXR), bind peroxisome proliferator response elements on target 
genes, and become transcriptionally active (142).  Protein-protein interactions are formed 
between different nuclear proteins called coactivators and corepressors, interacting with 
the PPAR-RXR heterodimer to upregulate or down regulate gene expression (143).  
Three subtypes of the PPAR family exist 
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Figure 1.  Peroxisome proliferator-activated receptors (PPARs) regulation of gene 
expression.  
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 (PPARγ, PPARα, PPARδ), each processing unique biological characteristics and tissue 
specifies. 
PPARα is primarily expressed in the muscle, heart, liver, and kidney where it is 
involved in the regulation of fatty acid catabolism (144; 145).  In fact, gene targets of 
PPARα function to conserve energy during fasting and feeding. PPARδ is located 
ubiquitously with less defined function.  Research does indicate its role in keratinocyte 
differentiation, wound healing, and mediation of VLDL signaling (146; 147).  PPARγ is 
expressed in the adipocyte and macrophage where it functions in adipocyte 
differentiation, lipid storage, and glucose homeostasis.  
Physiological role of PPARγ and ligand activation 
PPARγ is the most adipose tissue specific of the 3 isoforms, and has been 
exhaustively researched as it pertains to lipid metabolism as well as other basic and 
clinical functions. PPARγ exist in 2 isoforms: PPARγ1 and PPARγ2.  PPARγ2 is 30 
amino acids longer than PPARγ1 at the N terminus and the dominant isoform selective 
for adipose tissue (148; 149).  PPARγ is regulated at the level of gene expression by 
pharmacological and endogenous ligand availability and through the phosphorylation 
status of PPARγ activity. PPARγ appears to be an important component in the regulation 
of developmental genes.  When the PPARγ gene is deleted in mice, the embryo is aborted 
at approximately 10 days of gestation due to placental insufficiency in the adipose, 
placenta, and cardiac tissues (150).  In one instance, the PPARγ-null homozygous mutant 
developed to term, yet the animal lacked adipose tissue and died by postnatal day 5, 
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further suggesting PPARγ is critical in the development of adipose tissue in vivo (150; 
151).  In vitro studies indicate similar findings.  The differentiation of adipocytes from 
PPARγ null embryonic stem cells were dependent on PPARγ gene dosage, while other 
organ tissues developed normally regardless of dose (152).  These data show PPARγ has 
a significant role in the formation of adipose tissue in vivo and adipocyte differentiation 
in vitro. 
PPARγ is activated by synthetic and natural ligands binding to the carboxyl-
terminal ligand-biding domain.  There are several naturally occurring ligands that bind to 
PPARγ with a low affinity; it has yet to be revealed a naturally occurring high affinity 
PPARγ ligand.  Several types of polyunsaturated fatty acids, such as linolenic acid, 
linoleic acid, and eicosapentaenoic acid, activate PPARγ at a micromolar concentration.  
Although some nuclear receptors bind to ligands in nanomolar concentrations, free fatty 
acids circulate within the human serum in a micromolar concentration; therefore, this is 
consistent (153; 154).  Diets containing polyunsaturated fatty acids have been shown to 
promote the same physiological effects as the synthetic PPARγ ligands, such as 
increasing insulin sensitivity and decreasing triglyceride levels (155).  Certain 
prostaglandins, such as 15-deoxy-∆12,14 –PGJ2, also function to activate PPARγ 
demonstrating an anti-inflammatory response (156).  Although it remains unclear 
whether this prostaglandin is present in adipose tissue, in vitro studies indicate it acts to 
stimulate adipocyte differentiation (93; 157).  Although a high affinity natural ligand has 
not been discovered, it appears PPARγ binds to a multitude of polyunsaturated fatty acids 
serving to regulate levels and mediate genes involved in glucose and lipid homeostasis. 
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Multiple synthetic PPARγ activated ligands have been identified, of which the 
most well known are the thiazolidinediones (TZD) or glitazones.  This class of drugs was 
first described for their ability to reduce insulin resistance and glucose levels without 
overexerting the pancreas to secrete insulin in type 2 diabetic rodent models (158).  In 
addition, these compounds were also associated with minimizing triglyceride and free 
fatty acid levels.  It was not until 1995 that TZDs were recognized as agonist for PPARγ 
(159).  Several classes of glitazones exist to treat type 2 diabetes in humans, including 
rosiglitazone (Avandia) and pioglitazone (Actos).  One medical issue surrounding the use 
of TZDs is their ability to promote increased food consumption and lipogenesis in 
rodents and humans.  When adult fatty rats are treated with insulin-sensitizing 
rosiglitazone, the effects are strikingly similar to those changes that take place with the 
onset of hyperphagia (4; 5).  Non-insulin dependent diabetic individuals clinically taking 
this medication often gain additional weight, when usually already overweight.  It is 
uncertain whether this effect is primarily a result of increased insulin sensitivity, 
increased fat cell differentiation, or both.  Some research suggest the activation of PPARγ 
by TZD may increase fat cell number while decreasing fat cell size, possibly explaining 
this receptors role in increased insulin sensitivity and adipogenesis (160).  The 
mechanism underlying the activation of PPARγ by TZDs to produce insulin sensitivity 
remains unclear.  Obesity and insulin resistance are linked, yet this receptor is primarily 
found in the adipose tissue and is known to produce adipogenesis; therefore, this receptor 
is a novel physiological control.  Nevertheless, it is important to understand obesity and 
adipose cell differentiation are not identical.  Obesity is a disorder in which energy 
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balance is not achieved, whereas increased fat cell number does not always lead to 
obesity and insulin resistance unless total energy stores are increased.  Although TZDs 
are synthetic ligands, they have provided extensive insight into the biological function of 
PPARγ, providing explanations for such effects. 
PPARγ is predominantly found in adipose tissue but is also expressed in other 
tissues such as the liver and muscle (161).  High affinity ligands such as TZDs may 
stimulate all these tissue sites to produce alterations in gene expression that eventually 
induce insulin sensitivity.  Cell culture studies indicate ligand activation of the PPARγ is 
part of a positive feedback loop.  When treated with the TZD, troglitazone, mice 
genetically altered to lack adipose tissue showed improved insulin sensitivity (94).  This 
suggests that the regulation of PPARγ can take place in the absence or near absence of 
adipose tissue, indicating the action of PPARγ receptors partially occurs in adipocyte- 
independent pathways.  PPARγ ligands produce a coordinate activation of this receptor 
both directly and indirectly to increase expression in the skeletal muscle and liver to 
promote insulin sensitivity. 
PPARγ agonists may produce insulin sensitivity indirectly by lowering fatty acid 
levels in the muscle and liver thus altering glucose metabolism in these tissues (162).  In 
muscle, PPARγ agonists provoke the Randle cycle, which occurs when glucose and fatty 
acids compete for use as energy substrate (163).  This influx of free fatty acid levels 
prevents glucose disposal in the muscle.  In the liver, this influx of fatty acids promotes 
increased gluconeogenesis.  These physiological occurrences in the muscle and liver 
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induced by PPARγ agonists increase uptake and storage of fatty acids in the adipocyte, 
causing decreased triglyceride and free fatty acids in circulation (163). 
TZDs activation of PPARγ also increases adipose cell differentiation.  When 
energy intake does not exceed energy expenditure, the body produces more fat cells that 
are smaller in size yet more sensitive to insulin.  These occurrences may invoke insulin 
sensitivity (94; 160; 164). 
As discussed above, TZDs promote glucose utilization in skeletal muscle and 
decrease de novo glucose synthesis in the liver of type 2 diabetics (7; 165).  PPARγ found 
in adipocytes may regulate glucose metabolism in the liver and muscle by the secretion of 
endocrine signaling molecules.  Two possible signaling molecules produced by adipose 
cells are the cytokines, TNF-α and leptin, both of which are repressed by PPARγ agonists 
(166; 167).  TNF-α is known as an inhibitor of adipocyte differentiation, mediated by the 
down regulation of PPARγ.  Research shows elevated levels of TNF-α in vivo and in 
vitro may cause insulin resistance.  In fact, mice knockouts lacking TNF-α or its receptor 
develop insulin resistance (168; 169).  Hofmann et al showed treatment with TZDs for a 
2 week period reduced adipose TNF-α mRNA expression by 50% (166).  The role of 
leptin on insulin sensitivity remains unclear, but in vitro studies suggest leptin can 
interfere with insulin signaling in various cell types (7).  Qian et al showed rodents 
treated with leptin for 5 days increased PPARγ expression by 70-80% at both 3 and 8 
months, suggesting PPARγ may be associated with leptin-induced adipocyte apoptosis 
signal pathway (170).  PPARγ agonists may induce insulin sensitivity by decreasing 
TNF-α and increasing adipose tissue for secretion of leptin.  
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Transcriptional Cascade and Adipogenesis 
Adipogenesis is the differentiation of fat cells from preadipocytes into adipocytes.  
These mature adipocytes are lipid filled expressing and secreting several hormones and 
cytokines.  To support cell turnover and excess energy storage, adipogenesis is a normal 
developmental occurrence, taking place during the prenatal and postnatal periods.  
Several transcription factor families have emerged that are pivotal components in the 
early phases of cell growth into the differentiated adipocyte.  These are PPARγ, 
CCAAT/enhancer-binding protein (C/EBP), and sterol regulatory element-binding 
protein 1 (SREBP-1) (112; 171). 
Several studies first described expression and activation of PPARγ driving 
fibroblast and myoblasts to efficiently differentiate into mature adipocytes (6; 172).  
Other studies further demonstrated insulin resistant rodents treated with PPARγ agonists 
instead showed minimal large adipocyte formation, while producing more small 
adipocytes in the white adipose tissue (160; 164).  These detailed studies provide strong 
evidence to support PPARγ’s pivotal role in adipocyte differentiation and the foundation 
to research linking PPARγ to other transcription factors.  PPARγ interacts with other 
transcription factors such as C/EBPs and ADD1/SREBP1.  Together, these factors 
regulate adipogenesis through a sequential cascade of events regulated at the level of 
transcription, essentially explaining activation of C/EBP and PPARγ.  C/EBPβ and 
C/EBPδ induce expression of PPARγ through transcriptional control (173).  PPARγ is 
stimulated by ligands and thus begins adipogenesis.  C/EBPα is induced later in 
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differentiation, yet it is capable of synergizing with PPARγ to maintain elevated PPARγ 
levels.  The mechanism responsive for their interaction remains unclear.  C/EBPα is 
expressed in several tissue types, even inducing adipogenesis when expressed at high 
levels (174).  However, when expressed in adipose tissue, C/EBPα functions with PPARγ 
through binding sites in the PPARγ promoter to create an adipogenic response.  
ADD1/SREBP1, a second transcription factor, was first recognized for its effects 
in cholesterol regulatory genes (175) also acting as a key component in adipogenesis and 
fatty acid metabolism (176).  In addition, this transcription factor has also been shown to 
function with PPARγ in adipocyte determination and differentiation.  Coexpression 
increases PPARγ expression without ligand activation.  It appears this activation is 
possible because ADD/SREBP1 has a unique ability to induce the expression of several 
major genes in fatty acid metabolism, such as fatty acid synthase and lipoprotein lipase, 
providing high levels of endogenous ligands for PPARγ, causing transcriptional activity 
(135). 
The implication that childhood obesity is a critical starting point to the manifestation 
of obesity in adults creates an intriguing area of research.  Moreover, this period of rapid 
growth needs to be better understood and used as a strategy to control associated health 
problems.  Therefore, these research projects described in the following sections were 
completed to better understand the coordinated changes in genes and pathways that 
mediate hyperphagia during a brief developmental period in the fatty rat.  This model 
system provides a foundation to understand cellular and molecular mechanisms that may 
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influence the early onset of obesity in children.  We propose the activation of pathways 
regulated by PPARγ promote insulin sensitivity and the onset of hyperphagia.   
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PART 3.   INSULIN SENSITIVITY AND DEVELOPMENT OF 
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Abstract 
The onset of hyperphagia in the Zucker fatty (fa/fa) rat occurs on a single day in 
postnatal development and could be driven by increased insulin sensitivity.  To test this 
hypothesis, we performed insulin tolerance tests at several points in development.  In 
rapidly growing juvenile rats, fatties are as insulin sensitive as leans at 4 weeks of age, 
and became increasingly insulin resistant as they become obese.  During the suckling to 
weaning transition, fatties are insulin resistant at 2 weeks of age, when they are 
exclusively suckling; they are also insulin resistant at 3 weeks of age, when they are 
suckling and consuming solid food, but not hyperphagic.  By 4 weeks of age, when fatties 
are hyperphagic, fatties are as insulin sensitive as their lean littermates.  These data 
indicate that fatties experience two phases of insulin resistance, punctuated by a brief 
period of insulin sensitivity that follows the onset of hyperphagia.  To determine whether 
the increase in insulin sensitivity could be driving the onset of hyperphagia, insulin 
tolerance tests were performed from 21 to 27 days of age.  Fatties and leans became 
increasingly insulin resistant from 21 days to 23 days of age, then became as insulin 
sensitive as leans by 25 days of age.  These data show that increased insulin resistance 
precedes the onset of hyperphagia and increased insulin sensitivity follows the onset of 
hyperphagia.  This pattern suggests that developmental perturbations in insulin signaling 
are likely to be involved in the onset of hyperphagia. 
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Introduction 
Zucker fatty (fa/fa) rats inherit a leptin receptor mutation that causes early onset 
obesity (104).  Fatties grow at the same rate as their lean littermates for the first 22 days-
of-age, then suddenly begin to grow at a much higher rate (3).  This dramatic increase in 
growth rate corresponds with the emergence of hyperphagia in fatties, and is 
accompanied by the onset of hyperinsulinemia.  Fatties become visibly distinguishable 
from their lean littermates at this age by the expansion of their bellies with food, and 
within a few days they also become visibly obese (3). 
This increase in growth is easily detectable when fatties remain with their dams 
through the fourth week of life, but is obscured when fatties are separated from their 
dams at three weeks-of-age, which is a common husbandry practice.  The fact that the 
onset of hyperphagia occurs at such a precise age without the introduction of 
environmental changes suggests that a developmentally regulated mechanism determines 
the timing of the onset of hyperphagia. 
The weaning transition is associated with many physiological changes, including 
changes in insulin sensitivity in adipose tissue in normal rats.  Suckling rats consume a 
high fat, low carbohydrate diet and are somewhat insulin resistant (177-179).  
Furthermore, the expression of PPARγ, a transcription factor that controls the expression 
of insulin sensitizing pathways, is very low during the first two weeks of life and 
increases to adult levels during the weaning transition (8).  An increase in insulin 
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sensitivity during this period could contribute to the onset of hyperphagia by stimulating 
pathways for glucose disposal.   
An analogous situation occurs when adult fatties are treated with PPARγ receptor 
agonists.  Fatties become increasingly insulin resistant as they become obese (180), and 
their hyperphagia also lessens as they become obese and insulin resistant (125).  
However, treatment of insulin resistant obese adult fatties with thiazolidinediones 
increases insulin sensitivity and stimulates hyperphagia (4).  These observations suggest 
that an increase in insulin sensitivity could also play a role in the emergence of 
hyperphagia in fatties during the weaning transition.  To determine the relationship 
between insulin resistance and the emergence of hyperphagia in fatty rats, we measured 
insulin tolerance under several developmental conditions.   
Materials and Methods 
Animals 
Animals were produced in the principal investigator’s colony of partially inbred 
(F15-F17) ZUCKER-fa rats.  Animals are housed in plastic breeder boxes with ad libitum 
access to Teklad 8640 Rodent Diet and tap water.  The light cycle is maintained at 12 
hours of dark, followed by 12 hours of light.  The room temperature is maintained at 68 
to 74°F and 55 to 60% humidity.  All animal studies were reviewed and approved by the 
University of Tennessee Institutional Animal Care and Use Committee. 
The population is maintained with brother by sister matings to minimize 
extraneous genetic variation and with selection for large litter size to minimize inbreeding 
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depression.  Sires are removed when the dams appear pregnant.  The day of birth is 
considered 0 days of age.  Neonates are genotyped for fa during the first week of life, as 
described in detail below.  Litters are reduced to 8 pups during the first ten days of life by 
decapitating excess pups.  This is done to reduce variation in growth due to litter size.   
Pups are weighed daily from 14 days of age to the end of each experiment to acclimate 
them to handling and to generate growth curves.  Pups remain with their dams until 28 
days of age. 
Genotype detection 
Pups are marked by toe-clipping, and a single toe from each pup is saved to 
prepare DNA by the HotSHOT method (3; 181).  Briefly, toes are collected into 200 µl 
thermal cycler tubes.  Seventy-five microliters of 25 mM NaOH/ 0.2 mM EDTA/ pH 12 
are added to the tubes.  Samples are heated to 95 degrees C for 30 minutes, and then 
cooled to room temperature.  Seventy-five microliters of 40 mM Tris HCl/ pH 5 are 
added to each tube to adjust the pH to 8.  The DNA is then ready for PCR amplification. 
The fa mutation creates a restriction site for Msp I that can be used to detect fa 
genotype (104).  However, Msp I occasionally fails to cut DNA to completion in our 
hands, which can cause genotype misclassification.  To overcome this problem, we 
engineered an alternative restriction site by a strategy that has been described previously 
(182).  PCR primers were designed to amplify 101 base pair (bp) of DNA flanking the fa 
mutation.  The reverse primer, RLepr, was selected to anneal adjacent to the site of the 
mutation, and a single base substitution (C→G) was made in the second base from the 3’ 
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end of the primer to create a Pvu II restriction site in the wildtype allele and no restriction 
site in the mutant allele.  The primer sequences are fLepr, 5’-
CGTATGGAAGTCACAGA-3’, and RLepr, 5’GAATTCTCTAAATATTTCAGC-3’; the 
base substitution in RLepr is underlined.  Primers are mixed at 500 nM each in 50mM 
KCl, 10mM Tris-HCl (pH 9 at 25°C), 0.1% Triton X-100, 1.5 mM MgCl2, 0.2 mM each 
dATP, dCTP, dGTP and dTTP, 0.25 units Taq DNA polymerase and 2 µl of HotSHOT 
DNA in a 22 µl volume.  PCR amplification is carried out in a Robocycler thermal 
controller (Stratagene, La Jolla, CA) at 95°C for two min, followed by 40 cycles of 95°C 
for 30 sec, 45°C for 45 sec and 72°C for 30 sec.  Twenty µl of PCR product are digested 
with 1 unit Pvu II (New England Biolabs, Beverly MA) in a 30 µl volume for 1 h at 
37°C.  Thirty µl of Pvu II treated PCR product are loaded onto a 3% 3:1 high-resolution 
blend agarose (Amresco) gel and electrophoresed 30 minutes at 5 volts/cm.  Gels are 
stained with ethidium bromide and exposed to UV light.  The wildtype genotype 
produces an 80 bp band, and the mutant genotype produces a 101 bp band; both bands are 
visible in heterozygotes. 
Insulin Tolerance Tests 
Preliminary insulin tolerance tests, in which blood glucose was measured at 
multiple time points after insulin injection, determined that blood glucose levels reach a 
nadir 30 minutes after injection of 0.5 units/kg of insulin (Humulin R, Eli Lilly 
Pharmaceuticals).  Therefore, we used a simplified insulin tolerance test to assess the 
development of insulin resistance in fatty rats.  Rats were fasted two hours, then the tip of 
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the tail was nicked with a scalpel blade, a drop of blood was expressed onto a blood 
glucose test strip, and glucose values were measured with a glucose meter (Prestige 
Smart System, Walgreens).  After measuring fasting glucose, rats were injected 
subcutaneously with 0.5 units/kg of insulin.  A second glucose measurement was made 
30 minutes after insulin injection, and the rats were returned to their home cage with ad 
libitum access to food and water.  This simplified insulin tolerance test reduces the stress 
to the animals.  It also limits the number of incisions that must be made in the tail and 
enables the same subjects to be tested repeatedly across development. 
Experimental design 
Development of insulin resistance in juvenile fatties 
An initial experiment was performed to establish the course of development of 
insulin resistance in fatty rats under our experimental conditions.  Sex-matched fatty and 
wildtype littermates (N=24) were separated from their dams at 24 days of age and housed 
in pairs.  Insulin tolerance tests were performed at 28, 35, 42, 49, and 56 days of age on 
the same set of rats. 
Development of insulin sensitivity during the weaning transition.  
The transition from suckling to weaning includes substantial changes in diet 
composition and food intake in fatties and their lean littermates.  At 14 days of age, pups 
obtain all their nutrients from the dam.  At 21 days of age, pups are suckling and 
consuming solid food and fatties are not yet hyperphagic, hyperinsulinemic or visibly 
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obese.  By 28 days of age, pups are obtaining most of their nutrients from solid food and 
fatties are hyperphagic, hyperinsulinemic and visibly obese.  To test the hypothesis that 
changes in insulin sensitivity occur across this interval, insulin tolerance tests were 
performed at 14, 21 and 28 days of age on the same set of rats.  Rats were housed with 
their dams throughout this period, except during fasting and insulin tolerance tests to 
minimize investigator-induced changes in experimental conditions. 
Development of insulin sensitivity and hyperphagia in fatty rats. 
The results of the previous experiment suggested that changes in insulin 
sensitivity could be driving the onset of hyperphagia.  To test this hypothesis, rats were 
housed with their dams throughout this period, except during fasting and insulin tolerance 
tests.  Insulin tolerance tests were performed at 21, 22, 23, 24, 25, 26, and 27 days of age, 
using different litters for each age group.  It was necessary to use different sets of rats for 
each age because it takes a couple of days to recover from insulin tolerance tests. 
Statistical analyses  
Data were analyzed under mixed linear models using Proc Mixed of SAS Version 
8.2.  Genotype and sex were treated as fixed effects factors.  Age and litter were treated 
as random effects factors. 
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Results 
Development of insulin resistance in juvenile fatty rats  
Fatties begin to develop overt obesity during the fourth week of life and rapidly diverge 
from their lean littermates in subsequent weeks.  To establish the development of insulin 
resistance in fatty rats during this period of rapid growth and expansion of adipose mass, 
we performed insulin tolerance tests weekly from 28 to 56 days of age.  Fatties were 
already visibly obese by 28 days of age and slightly heavier than their wildtype 
littermates (wildtypes 64.3 g vs fatties 67.2 g, Fig. 2).  They continued to diverge 
thereafter, with fatties gaining 46 grams per week compared to 29 grams per week for 
wildtypes.  During this period of rapid growth, fasting glucose levels were similar among 
all genotype and age groups (Fig. 3).  In contrast, the response of blood glucose to insulin 
injection showed marked age and genotype differences.  At 28 days of age, blood glucose 
after insulin injection was similar in wildtypes and fatties.  By 42 days of age, blood 
glucose values after insulin injection were higher in fatties, and by 56 days of age, fatties 
did not lower their blood glucose in response to this dose of insulin (Fig. 4). These data 
demonstrate that fatties are insulin sensitive at 4 weeks of age and become increasingly 
insulin resistance in parallel with the increase in body weight during this period of rapid 
growth. 
Insulin resistance in suckling fatties 
From the second week of life to the fourth week of life, rat pups change from reliance on 
their dam for all their nutrients to feeding independently on solid food.  To 
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Figure 2.  Daily body weight during juvenile development.  Fatties are visibly obese 
by 28 days of age, and their body weights are significantly heavier.  Fatties gain 67.2 g 
per week over the next 4 weeks, while wildtypes gain 64.3 grams per week. 
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Figure 3.  Insulin tolerance during juvenile development.  Fasting glucose levels are 
not affected by genotype from 4 to 8 weeks of age.  Fatties are as sensitive to insulin as 
wildtypes at 28 days of age.  Fatties become insulin resistant by 42 days of age.  By 56 
days of age, fatties are unresponsive to 0.5U/kg insulin; genotype by age *P < .0001.  
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Figure 4.  Body weights during the suckling to weaning transition.  Body weights of 
fatties and wildtypes were similar at 14 and 21 days of age. By 28 days, fatties were 
significantly heavier than heterozygotes  (P < 0.0001) and wildtypes (P = 0.0449).  
Letters above the bars are similar for groups with similar means.   
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establish the response to insulin across this transition, we performed insulin tolerance 
tests at 14, 21 and 28 days of age.  At 14 and 21 days of age all genotypes had similar 
body weights (Fig. 4).  However, by 28 days of age, fatties were slightly heavier than 
lean rats and were visibly obese.  In all genotypes, fasting glucose values at 14 and 21 
days of age were higher than levels at 28 days of age (Fig. 5).  These observations 
indicate glucose metabolism is altered in both lean and fatty rats between 21 and 28 days 
of age.  Thirty minutes after a 0.5 U/kg insulin injection, fatty rats maintained higher 
glucose levels than lean rats at 14 and 21 days of age (Fig. 5).  By 28 days of age, fatty 
and lean rats converged at similar low levels of blood glucose following the same dosage 
of insulin.  Thus, fatty rats become insulin sensitive between 21 and 28 days of age.   
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Figure 5.  Insulin tolerance during the suckling to weaning transition.  Fasting 
glucose levels decrease between 21 and 28 days of age in all genotypes groups; age, P < 
0.0001.  Fatties are insulin resistant at 14 and 21 days of age and, by 28 days of age, 
fatties become as sensitive to insulin as lean rats ; age X genotype,  P < 0.0001. 
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These data indicate that fatty rats are insulin resistant prior to the onset of 
hyperphagia, hyperinsulinemia, and overt obesity, but are insulin resistant after the onset 
of hyperphagia. 
Response to insulin during the fourth week of life 
We have seen that fatties change from being insulin resistant to insulin sensitive 
from 21 to 28 days.  This interval includes the age when fatties begin to gain weight at a 
higher rate than lean rats as a consequence of the emergence of hyperphagia (3).  In many 
experiments, we have found that fatty rats develop robust hyperphagia quite suddenly 
after 22 days of age.  This increase in food intake can be detected as an increase in daily 
weight gain at 23 days of age.  To determine when this change in insulin sensitivity 
occurs relative to the onset of hyperphagia, we performed insulin tolerance tests daily 
from 21 to 27 days of age.   
In this experiment, daily weight gain of fatty rats exceeded that of lean rats at 23 
days of age, precisely the same age as in many previous experiments (Fig. 6).  At 21 days 
of age blood glucose levels 30 minutes after insulin injection were higher in fatties 
compared to their lean littermates (Fig. 7).  Although this pattern was maintained at 22 
and 23 days of age, blood glucose 30 minutes after insulin injection shifted upwards in 
both lean and fatty rats at these ages, suggesting that both groups became slightly more 
insulin resistant at these ages.  After 23 days of age, the peak of insulin resistance 
decreased.  By 25 days of age, fatties and their lean littermates had similar levels of blood 
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Figure 6.  Daily weight gain during the fourth week of life.  Fatties gain less weight 
than wildtypes at 21 days of age.  At 22 days of age, daily gains of fatties and wildtypes 
are similar.  At 23-26 days of age, daily gains are significantly higher in fatties than 
wildtypes; genotype by age *P < 0.0001.  These data replicate a pattern we have 
described previously – daily gain increases in fatty rats after 22 days of age.  This 
corresponds with the onset of hyperphagia. 
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Figure 7.  Insulin tolerance during the fourth week of life.  For clarity, only glucose 
values 30 minutes after insulin injection are shown here.  Fatties are insulin resistant from 
21 to 24 days of age.  By 25 days of age, fatties have become insulin sensitive; genotype 
by age *P < 0.0001.  These data demonstrate that whole body insulin sensitivity increases 
in fatty rats after the onset of hyperphagia. 
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glucose thirty minutes after insulin injection (Fig. 7).  These data indicate that a transient 
increase in insulin sensitivity begins prior to the onset of hyperphagia, and that an 
increase in insulin sensitivity evolves a few days after the onset of hyperphagia.   
Discussion 
The Zucker fatty rat (fa/fa) experiences insulin resistance during two phases of 
development.  The early phase of insulin resistance occurs during the suckling period 
before the onset of hyperphagia, hyperinsulinemia and overt obesity.  Hyperphagia 
emerges in fatties at 23 days of age and is accompanied by elevated plasma insulin and 
rapid development of overt obesity (3).  After the onset of hyperphagia, fatties rapidly 
become as insulin sensitive as their lean littermates.  This insulin sensitive phase is fairly 
brief; as they become more obese over the next few weeks, fatties gradually become 
insulin resistant again. 
The early phase of insulin resistance probably reflects a lack of leptin signaling 
uncomplicated by hyperinsulinemia and obesity.  While fatties have high leptin levels, 
their leptin signaling is low because of a defect in the leptin binding domain of the leptin 
receptors (104).  In this respect, they are similar to mice that are leptin deficient because 
they lack adipose tissue.  These mice produce very little leptin and are also insulin 
resistant.  Treatment with exogenous leptin improves insulin resistance in this model, and 
in humans with lipodystrophies (82; 91).  Because leptin signaling cannot be restored in 
fatty mutants after the onset of hyperphagia, the development of insulin sensitivity in this 
period must be mediated by mechanisms that are independent of leptin signaling. 
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The transition from the early phase of insulin resistance to the insulin sensitive 
phase is more complex than a simple increase in responsiveness to insulin.  Instead, the 
response of blood glucose to insulin injection resembles a roller coaster ride – there is a 
gradual increase in insulin resistance prior the onset of hyperphagia, a peak at the onset of 
hyperphagia and a drop in insulin resistance following the onset of hyperphagia.  This 
pattern has two implications.  First, it suggests that increased insulin sensitivity does not 
drive the onset of hyperphagia as we initially proposed.  Instead, increased insulin 
sensitivity seems to follow the onset of hyperphagia.  Second, the fact that an increase in 
insulin resistance precedes the onset of hyperphagia and peaks at the onset of 
hyperphagia suggests that the mechanism that activates hyperphagia is related to 
increased insulin resistance. 
An increase in lipogenesis in adipose tissue is one factor that probably contributes 
to the development of insulin sensitivity after the onset of hyperphagia.  The increase in 
insulin secretion that accompanies a higher level of food intake contributes to the 
increase in lipogenesis at this age.  However, the onset of hyperphagia and 
hyperinsulinemia emerges with striking amplitude at 23 days of age.  We have shown 
elsewhere that the weight of the stomach contents increases in fatties by approximately 
80% at 23 days of age and insulin levels increase by 140 % at this age (3).  In contrast, 
the transition from an insulin resistant state to an insulin sensitive state requires a period 
of adaptation of a couple of days.  This is likely to involve changes in other signaling 
molecules that improve the ability to respond to the increased insulin levels, such as 
PPARγ.   
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PPARγ is a transcription factor that improves insulin sensitivity by stimulating the 
expression of genes for glucose disposal and lipogenesis in adipose tissue.  PPARγ 
mRNA levels are low at 15 days of age and reach a peak at 23 days of age in wildtype 
rats (8).  This corresponds with the ages when rats in our studies become increasingly 
insulin resistant, which suggests that the changes in insulin resistance and PPARγ mRNA 
expression could be linked.  Furthermore, when insulin resistant adult fatty rats or human 
diabetics are treated with thiazolidinediones, a class of PPAR agonists, their insulin 
sensitivity improves and their appetite is also stimulated (4; 7).  These observations 
suggest that developmental changes in PPARγ expression could be an important part of 
the changes in insulin sensitivity in response to hyperphagia, or perhaps a part of the 
mechanisms that triggers the onset of hyperphagia. 
Although we have shown that the onset of hyperphagia occurs at 23 days of age in 
fatties raised under standard husbandry conditions, it should be noted that others have 
demonstrated that fatties will consume greater amounts of food earlier than this age when 
individual food intakes are measured under other experimental conditions.  When rats are 
separated from their dams for four hours and housed with their siblings, then transferred 
to individual test chambers with access to half and half (milk and cream), fatties 
consumed more half and half at 12, 15 and 18 days of age (123).  This experiment 
suggests that the pathways that stimulate hyperphagia can influence food intake earlier 
than 23 days of age.  It is possible that these pathways are stimulated by maternal 
deprivation or some property of the diet.  The fact that fatties are not hyperphagic under 
standard husbandry conditions suggests that the onset of hyperphagia is also dependent 
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on other factors.  These factors could be related to diet composition, the thermal 
environment, maternal interactions, or developmentally programmed changes in 
metabolism.  On this note, the increase in PPARγ expression during the weaning 
transition does not differ between rats weaned onto high carbohydrate versus high fat 
diets, but occurs independent of diet composition.  Thus, PPARγ expression is regulated 
by developmental factors rather that diet during the weaning transition (8).   
These data show a dynamic relationship between insulin sensitivity and the fatty 
phenotype that is closely related to hyperphagia.  Not only are there long term changes in 
insulin resistance from the age when fatties are not obese or hyperinsulinemic to the age 
when they are massively obese, but there are also short term changes in insulin sensitivity 
around the onset of hyperphagia that suggest that some developmental perturbation of 
insulin signaling is related to the onset of hyperphagia.  The increase in expression of 
PPARγ at this age, and the fact that PPARγ agonists not only improve insulin signaling, 
but also stimulate lipogenesis and hyperphagia in adult fatties (4), suggest that this 
transcription factor could be a critical component of the activation of hyperphagia. 
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PART 4.  PPARγ EXPRESSION RELATIVE TO THE ONSET OF 
HYPERPHAGIA IN ZUCKER FATTY RATS 
  67
Abstract 
Hyperphagia emerges suddenly after 22 days of age in Zucker fatty (fa/fa) rats, 
and fatties become visibly obese within days.  This rapid increase in growth rate was 
associated with increased insulin sensitivity.  The objective of these experiments was to 
determine whether changes in expression of PPARγ, a transcription factor that enhances 
insulin sensitivity and lipogenesis, were related to the onset of hyperphagia in fatties.  
Quantitative RT-PCR for PPARγ and FAS mRNA showed that neither of these were 
differentially expressed before the onset of hyperphagia, but both were induced in fatties 
after the onset of hyperphagia.  Western blots showed PPARγ and FAS proteins were low 
in adipose tissue of lean and preobese rats at 21 days of age, before the onset of 
hyperphagia.  A large induction of PPARγ and FAS occurs after the onset of 
hyperphagia, as fatties become insulin sensitive.  By 28 days of age, PPARγ and FAS 
expression were dramatically induced in fatties, but remain low in their lean littermates.  
These data show that PPARγ expression increased in fatty rats in parallel with the 
increased insulin sensitivity that follows the onset of hyperphagia, suggesting that PPARγ 
signaling may contribute to the timing of the onset of hyperphagia. 
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Introduction 
The obesity epidemic in the United States has been accompanied by an alarming 
increase in the prevalence of overweight children (1).  Data from the National Health and 
Nutrition Examination Survey (NHANES) indicate that the number of overweight 
children has increased among all age, race, and sex groups.  Overweight children are at 
high risk for becoming overweight adults and developing hypertension and type II 
diabetes (2).  These observations underscore the importance of understanding the early 
development of energy balance regulatory systems, particularly during critical periods of 
rapid growth.   
The Zucker fatty (fa/fa) rat provides a unique model for understanding the early 
development of obesity.  Fatties grow at approximately the same rate as their lean 
littermates for the first 22 days of age (3).  At 23 days of age, fatties develop robust 
hyperphagia, which dramatically increases growth rate and expansion of fat mass (3).  
Fatties become visibly obese within a few days of the onset of hyperphagia.  This 
developmental pattern suggests that a fundamental change in the regulation of energy 
balance occurs at this age.   
The onset of hyperphagia is accompanied by a marked change in insulin 
sensitivity.  It is well known that juvenile fatty rats are insulin sensitive and become 
increasingly insulin resistant as their adipose mass expands.  We have shown that fatties 
are also insulin resistant prior to the onset of hyperphagia, hyperinsulinemia and overt 
obesity, and then become insulin sensitive with the emergence of hyperphagia.  Thus, 
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fatties experience two phases of insulin resistance separated by a brief phase of insulin 
sensitivity that follows the onset of hyperphagia (Thesis Chapter 3). 
It is likely that the early phase of insulin resistance that exists prior to the onset of 
hyperphagia primarily reflects the absence of leptin signaling.  The best evidence for a 
role of leptin in countering insulin resistance is derived from animals that lack adipose 
tissue.  These models produce very little leptin and are insulin resistant.  Small amounts 
of adipose tissue or exogenous leptin injections improve their insulin sensitivity (91).  
Exogenous leptin injections also improve insulin resistance in people with congenital 
generalized lipodystrophies (80; 82).  These observations support the hypothesis that 
insulin resistance develops early in life in fatty rats, before the onset of hyperinsulinemia 
and obesity, because of the reduction in leptin signaling. 
Leptin promotes insulin sensitivity by enhancing the expression of peroxisome 
proliferator-activated receptors (PPARs) (170).  Peroxisome proliferator-activated 
receptor gamma (PPARγ) is a transcription factor that stimulates adipocyte differentiation 
and expression of genes for glucose uptake and lipogenesis (6; 183).  Thiazolidinediones 
(TZD) improve insulin sensitivity by activating PPARs, which stimulates glucose uptake 
and lipogenesis by adipose tissue in diabetics (7; 159).  When insulin resistant adult 
fatties are treated with thiazolidinediones, they not only improve their insulin sensitivity, 
but also increase their food intake and growth (4).  These responses are remarkably 
similar to those that occur developmentally in fatties at the onset of hyperphagia, 
suggesting that activation of PPARs could also be involved in the development of 
hyperphagia. 
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There are developmental changes in PPARγ mRNA levels during the same 
interval as the onset of hyperphagia in fatties. PPARγ  mRNA expression in adipose 
tissue increases during the suckling period in rats; levels are low at 15 days of age and 
reach a maximum by 23 days of age (8).  This developmental pattern is independent of 
changes in the fat content of the diet.  It is possible that the increase in PPARγ expression 
contributes to the onset of hyperphagia at this age by inducing genes for glucose 
utilization and lipogenesis in adipose tissue, just as the activation of PPARγ does in adult 
fatties. 
The fact that a rise in PPARγ mRNA expression occurs at the same age as an 
increase in insulin sensitivity, food intake and growth in fatties suggests that these two 
events are linked.  The purpose of this study was to compare the expression of PPARγ in 
lean and fatty rats at key points in development to determine the relationship between 
PPARγ expression and the development of hyperphagia and obesity.  We also evaluated 
the expression of fatty acid synthase (FAS) as a marker for lipogenesis at these ages.   
Materials and Methods 
Animals   
Animals were produced in the principal investigator’s colony of partially inbred 
(F15-F17) ZUCKER-fa rats.  Animals are housed in plastic breeder boxes with ad libitum 
access to Teklad 8640 Rodent Diet and tap water.  The light cycle is maintained at 12 
hours of dark, followed by 12 hours of light.  Room temperature is maintained at 68 to 
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74°F and 55 to 60% humidity.  All animal studies were reviewed and approved by the 
University of Tennessee Institutional Animal Care and Use Committee. 
The population is maintained with brother by sister matings to minimize 
extraneous genetic variation and with selection for large litter size to minimize inbreeding 
depression.  Sires are removed when the dams appear pregnant.  The day of birth is 
considered 0 days of age.  Neonates are genotyped for fa during the first week of life, as 
described in detail below.  Litters are reduced to 8 pups during the first ten days of life by 
decapitating excess pups. 
Pups are weighed daily from 14 days of age to the end of each experiment to 
acclimate them to handling.  Daily gain is calculated as the difference in weights on 
consecutive days.  Daily gain provides a marker for the onset of hyperphagia. 
Genotype detection   
Pups are marked by toe-clipping, and a single toe from each pup is saved to 
prepare DNA by the HotSHOT method (3; 181).  Briefly, toes are collected into 200 µl 
thermal cycler tubes.  Seventy-five microliters of 25 mM NaOH/ 0.2 mM EDTA/ pH 12 
are added to the tubes.  Samples are heated to 95 degrees C for 30 minutes, and then 
cooled to room temperature.  Seventy-five microliters of 40 mM Tris HCl/ pH 5 are 
added to each tube to adjust the pH to 8.  The DNA is then ready for PCR amplification. 
The fa mutation creates a restriction site for Msp I that can be used to detect fa 
genotype (104).  However, Msp I occasionally fails to cut DNA to completion in our 
hands, which can cause genotype misclassification.  To overcome this problem, we 
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engineered an alternative restriction site by a strategy that has been described previously 
(182).  PCR primers were designed to amplify 101 base pair (bp) of DNA flanking the fa 
mutation.  The reverse primer, RLepr, was selected to anneal adjacent to the site of the 
mutation, and a single base substitution (C→G) was made in the second base from the 3’ 
end of the primer to create a Pvu II restriction site in the wildtype allele and no restriction 
site in the mutant allele.  The primer sequences are fLepr, 5’-
CGTATGGAAGTCACAGA-3’, and RLepr, 5’GAATTCTCTAAATATTTCAGC-3’; the 
base substitution in RLepr is underlined.  Primers are mixed at 500 nM each in 50mM 
KCl, 10mM Tris-HCl (pH 9 at 25°C), 0.1% Triton X-100, 1.5 mM MgCl2, 0.2 mM each 
dATP, dCTP, dGTP and dTTP, 0.25 units Taq DNA polymerase and 2 µl of HotSHOT 
DNA in a 22 µl volume.  PCR amplification is carried out in a Robocycler thermal 
controller (Stratagene, La Jolla, CA) at 95°C for two min, followed by 40 cycles of 95°C 
for 30 sec, 45°C for 45 sec and 72°C for 30 sec.  Twenty µl of PCR product are digested 
with 1 unit Pvu II (New England Biolabs, Beverly MA) in a 30 µl volume for 1 h at 
37°C.  Thirty µl of Pvu II treated PCR product are loaded onto a 3% 3:1 high-resolution 
blend agarose (Amresco) gel and electrophoresed 30 minutes at 5 volts/cm.  Gels are 
stained with ethidium bromide and exposed to UV light.  The wildtype genotype 
produces an 80 bp band, and the mutant genotype produces a 101 bp band; both bands are 
visible in heterozygotes. 
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Experimental Design  
Expression of PPARγ and FAS mRNA before and after the onset of hyperphagia.   
This experiment was performed to determine whether PPARγ and FAS mRNA 
expression were affected by the onset of hyperphagia.  Rats were weighed daily from 14 
days of age until they were killed.  Daily weight gain was calculated as a marker for the 
onset of hyperphagia.  Sex-matched wildtype and fatty littermates were killed by 
decapitation at 20 or 24 days of age.  Stomachs and liver were dissected and weighed at 
the time of decapitation.  Stomach contents were removed and the empty stomachs were 
reweighed.  The difference between full stomach weight and empty stomach weight was 
calculated as a measure of stomach contents.  Inguinal adipose pads were dissected, 
weighed and frozen in liquid nitrogen for preparation of RNA and quantification of gene 
expression by real time-polymerase chain reaction assays (RT-PCR), as described below. 
Developmental changes in FAS and PPARγ protein expression.   
Because PPARγ expression is regulated at the level of translation, mRNA levels 
may be a poor indicator of PPARγ protein levels.  To establish the pattern of expression 
of PPARγ and FAS at key points in development, we measured the expression of PPARγ 
and FAS protein at 21, 28 and 60 days of age.  These ages represent different metabolic 
conditions.  At 21 days of age, fatties are insulin resistant compared to their littermates, 
but they have normal insulin levels, and they are not hyperphagic or visibly obese.  At 28 
days of age, fatties are insulin sensitive, hyperphagic, hyperinsulinemic, and mildly 
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obese.  At 60 days of age, fatties are insulin resistant, hyperphagic, hyperinsulinemic and 
massively obese.   
Rats were killed by CO2 asphyxiation for collection of inguinal adipose pads.  
Western blots were prepared with inguinal adipose tissue of lean and fatty sex matched 
pairs at 21, 28, and 60 days of age to determine PPARγ and FAS expression levels.  
Seven replicate western blots were prepared for PPARγ and 5 replicate blots were used 
for FAS expression analysis.   
Expression of FAS and PPARγ relative to the onset of hyperphagia.   
We have previously demonstrated that the onset of hyperphagia in fatties is 
accompanied by an increase in insulin sensitivity.  To determine the relationship between 
PPARγ and FAS expression, rats were killed by decapitation from 21 to 28 days of age.  
Inguinal adipose tissue was dissected and frozen for analysis of PPARγ and FAS 
expression by western blots.  There were 7 western blots prepared for PPARγ, and 5 blots 
were used for FAS expression analysis.  Each western blot includes samples from lean 
and obese pairs killed at each age.   
Tissue Processing  
RNA for quantitative real time-polymerase chain reaction assays (RT-PCR) was 
extracted using a Totally RNA kit.  The Totally RNA kit procedure for RNA extraction 
was modified to include two additional chloroform extractions immediately after 
homogenization of the tissues to remove lipids.  After isolation, RNA was dissolved in 
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DEPC-treated water, precipitated with LiCl and washed with 70% ethanol.  RNA was 
quantified spectrophotometrically in 1 mM Na2HPO4, pH 8.5 (184). 
Fifty ng of total RNA were mixed with 5 mM MgCl2, 300 µM each dNTPs, 62.5 
units Moloney murine Leukaemia Virus (MuLV) Reverse Transcriptase, 10 units RNase 
inhibitor (GeneAmp RNA PCR Core Kit; Applied Biosystems), 0.625 units AmpliTaq 
Gold DNA Polymerase, 1X Taqman buffer A (TaqMan 1000 RXN Gold with Buffer A 
Pack; Applied Biosystems) in a 25 µl volume.  The composition and concentrations of 
the primers and probes are listed in Table 2.  Amplification was performed in a Cepheid  
SmartCycler dilutions of RNA pooled from multiple samples. PPARγ and FAS 
expression levels were expressed as a ratio of 18S RNA expression levels. 
Table 2.  RT-PCR primer and probe concentrations and compositions. 
Oligo  Concentration Sequence 
FAS for 200 nM CCCAGAGGCTTGTGCTGACT 
FAS rev 400 nM CGAATGTGCTTGGCTTGGT 
FAS probe 100 nM TET d(CCGATCTGGAATCCGCACCGG) TAMRA 
PPAR for 200 nM TGCGAGTGGTCTTCCATCAC 
PPAR rev 400 nM GCCTTGAGCACTTCACAAGAAATT 
PPAR probe 100 nM CAL RED d(TTTGCCAAGCTGCTCCAGAAAATGA) 
BHQ-2 
18S for 200 nM AGTCCCTGCCCTTTGTACACA 
18S rev 400 nM GATCCGAGGGCCTCACTAAAC 
18S probe 100 nM 6-FAM d(CGCCCGTCGCTACTACCGATTGG) BHQ-1 
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Protein extracts were prepared by homogenization of inguinal adipose tissue in a 
buffer containing 100 mM Tris HCl, 510 mM sucrose, and 2 mM EDTA, pH 7.4.  
Protease inhibitors (2 µM phenylmethylsulfonyl fluoride, 1 µM pepstatin, 80 trypsin 
inhibitory milliunits aprotinin per ml, 10 µM leupeptin, 2 mM sodium orthovanadate, all 
from Sigma, St. Louis, MO) were added immediately before processing.  Adipose tissue 
was homogenized in 1 ml of ice-cold homogenization buffer per gram of tissue.  
Homogenates were centrifuged at 5000g for 2 minutes at 4ºC.  The supernatant was 
transferred to a fresh tube and centrifuged twice at 13000g for 15 minutes at 4ºC, and the 
supernatant was saved as the final sample protein extract.  Protein concentration of each 
sample extract was quantified by the Bradford method (Amresco, Inc., Solon, OH). 
SDS-PAGE and Western Immunoblotting  
Eighteen µg of protein from each extract were loaded on 10% SDS-PAGE gel for 
PPARγ and 8% SDS-PAGE gel for FAS and electrophoresed at 50 volts for 4 to 5 hours.  
The SDS-PAGE gel was electroblotted onto a polyvinyldifluoride membrane overnight at 
30 volts in 4 degrees C. 
Blots were blocked in 25 ml of blocking buffer (1X TBS, 0.1% Tween-20, and 
5% w/v nonfat dry milk) at room temperature for 1 hour.  Blots were incubated overnight 
at 4ºC with a polyclonal PPARγ (Cell Signaling Technology, Beverly, MA) or polyclonal 
FAS (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) primary antibody diluted 1:500 in 
10 ml of primary antibody dilution buffer (1X TBS, 0.1% Tween-20, and 5% w/v nonfat 
dry milk).  After the first incubation, blots were washed with a 1X Tris-buffered 
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saline/0.1% Tween-20 solution, and then incubated at room temperature for 1 hour with 
the appropriate secondary antibody diluted 1:2000 in 20 ml of blocking buffer.  Blots 
were washed with a 1X Tris-buffered saline/0.1% Tween-20 solution and bands 
corresponding to PPARγ and FAS were detected by chemiluminescence (Luminol, Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA).  Blots were stripped and immunoblotted as 
described above, using a primary antibody for β-actin (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA) diluted 1:500 in 10 ml of primary antibody dilution buffer and an 
appropriate secondary antibody diluted 1:2000 in 20 ml of blocking buffer.  Expression 
levels were quantified densitometrically.   
Statistical analyses 
Daily weight gain, body weights, tissue weights and stomach contents were 
analyzed using a mixed linear model, accounting for sex, genotype, and age as fixed 
effects, and litter as a random effect.  RT-PCR data were analyzed under mixed linear 
models using sex, genotype and age as fixed effects and litter as a random effect.  
Western blot data were analyzed under mixed linear models using genotype and age as 
fixed effects and blot number as a random effect.  These analyses were performed using 
Proc Mixed in SAS version 9.0 (The SAS Institute, Cary, NC). 
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Results 
Expression of FAS and PPARγ mRNA before and after the onset of hyperphagia. 
Many investigators routinely separate rat pups from their dams at 3 weeks of age.  
This type of investigator-initiated weaning typically disrupts growth of the pups.  In these 
experiments, rat pups remained with their dams until they were killed or reached 28 days 
of age.  Under these conditions, the daily gains of fatties exceed the daily gains of lean 
rats at 23 days of age (Fig. 8), replicating a pattern we have seen in many experiments.  
This increase in daily gain rapidly alters body weight; body weights are similar between 
wildtypes and fatties at 20 days of age, but fatties become heavier than wildtypes by 24 
days of age (Table 3). 
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Figure 8.  Expression of fatty acid synthase measured by quantitative RT-PCR in 
wildtype and fatty Zucker rats before and after the onset of hyperphagia.  FAS expression 
and 18S RNA were quantified by RT-PCR and the data were expressed as a ratio of FAS 
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to 18S RNA in arbitrary expression units.  FAS was not affected by genotype at 20 days 
of age, but became higher in fatties by 24 days of age, after the onset of hyperphagia.  
Letters above the bars are similar for groups with similar means.   
This sudden increase in daily weight gain strongly suggests that fatties begin 
consuming more food at this age.  While food intake is easily measured in adult rats, it is 
much more difficult to measure in suckling pups consuming both solid food and milk.  
However, the weight of the stomach contents is highly correlated with 24-hour food 
intake (185), making this measure a useful indicator of the level of food intake under  
the conditions of this experiment.  In this experiment, full stomach weights of wildtypes 
and fatties were similar at 20 days of age, but by 24 days of age fatties experienced a 
57% increase in full stomach weight over the wildtypes (Table 3).  The weights of the 
Table 3.  Effects of fa/fa genotype on body weight and tissue weights at 20 and 24 days 
of age. 
 DAY 20 DAY 24 
 +/+ fa/fa +/+ fa/fa 
Body weight,  
grams 
 
35.0 ± 0.8 
 
34.7 ± 0.9  
 
49.7 ± 0.9 
 
52.3 ± 1.1* 
Stomach weight,  
grams 
 
1.18 ± 0.09 
 
0.99 ± 0.10  
 
1.41 ± 0.16  
 
2.22 ± 0.16* 
Empty stomach  
weight, grams 
 
0.28 ± 0.02 
 
0.25 ± 0.02 
 
0.41 ± 0.02 
 
0.40 ±  .02 
Stomach contents  
weight, grams 
 
0.90 ± 0.09 
 
0.74 ± 0.10 
 
1.01 ± 0.16 
 
1.82 ± 0.16* 
Liver weight,  
grams 
 
1.14 ± 0.60  
 
1.17 ± 0.06  
 
1.90 ± 0.06 
 
2.32 ± 0.06* 
Inguinal adipose  
pads weight, grams 
 
0.31 ± 0.03 
 
0.75 ± 0.03* 
 
0.62 ± 0.06 
 
1.34 ± 0.06* 
Values are means ± standard errors.  Asterisks indicate where the mean of the fatties 
differ from the mean of age-matched wildtypes.  
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stomach tissues themselves were not affected by genotype at either age.  However, the 
weight of the stomach contents were similar between genotypes at 20 days of age, but at 
24 days of age the weight of the stomach contents was 80% higher in fatties than in 
wildtypes.  Furthermore, liver weight was unaffected by genotype at 20 days of age, but 
became 22% greater in fatties compared to wildtypes at 24 days of age.  These data 
confirm that the increased growth rate that emerges at 23 days of age is associated with 
the onset of robust hyperphagia. 
Note that inguinal adipose mass is already elevated prior to the onset of 
hyperphagia (Table 3).  The excess adipose mass that accumulates during the first three 
weeks of age is a consequence of reduced energy expenditure in fatties.   
At 20 days of age, before the onset of hyperphagia, fatties and wildtypes have 
similar low levels of FAS mRNA (Fig. 8).  From 20 to 24 days of age, FAS expression 
increases 22 fold in fatties.  PPARγ mRNA expression was also similar between 
wildtypes and fatties at 20 days of age, and increased in fatties 2- fold from 20 to 24 days 
of age (Fig.9).  These data demonstrate that the onset of hyperphagia is associated with a 
large induction of FAS mRNA in fatties, as expected, and a smaller induction of PPARγ 
mRNA.   
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Figure 9.  Expression of PPARγ measured by quantitative RT-PCR in wildtype and 
fatty Zucker rats at 20 and 24 day.  PPARγ expression and 18S RNA were quantified 
by RT-PCR and the data were expressed as a ratio of PPARγ to 18S RNA in arbitrary 
expression units.  PPARγ was not affected by genotype at 20 days of age, but became 
higher in fatties by 24 days of age, after the onset of hyperphagia.  Letters above the bars 
are similar for groups with similar means.   
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While FAS is regulated primarily at the level of transcription in response to 
insulin, expression of PPARγ expression is more dependent of translation, and analysis of 
expression of the protein could be more informative than the mRNA. 
Developmental changes in FAS and PPARγ protein expression.   
The purpose of this experiment was to determine the influence of the fatty 
genotype on PPARγ protein expression at three points in development that have different 
metabolic patterns.   
At 21 days of age fatties are insulin resistant, but not hyperinsulinemic, 
hyperphagic or obese.  FAS protein expression is low at this age in both lean and fatty 
rats (Fig. 10), which is consistent with the low levels of FAS mRNA in the previous 
experiment.  These low levels of FAS protein reflect the fact that lipogenesis is very low 
at this age.  PPARγ protein expression is also low in leans and fatties at 21 days of age 
(Fig. 10). 
By 28 days of age fatties are insulin sensitive, hyperinsulinemic, hyperphagic and 
moderately obese. At this age, FAS protein expression is upregulated in lean rats and 
further upregulated in fatties (Fig. 10).  PPARγ protein expression is also upregulated in 
fatties by 28 days of age (Fig. 11).  These results are also consistent with the pattern of 
FAS and PPARγ mRNA expression after the onset of hyperphagia in the previous 
experiment.   
By 60 days of age, fatties are again insulin resistant, hyperinsulinemic, 
hyperphagic and massively obese.  At this age FAS expression in leans has returned to  
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Figure 10.  FAS expression at 21, 28 and 60 days of age.  18 µg of inguinal adipose 
protein extracts were prepared at each of the 3 ages, separated by 8% SDS-PAGE, and 
analyzed using a Western blot technique.  FAS migrated as a 250 kilodalton (KD) protein 
on a 8% SDS-PAGE gel.  Blots were quantified and mean optical densities of 5 blots 
containing sex matched lean and obese pairs at each age were analyzed.  β-actin is shown 
to demonstrate equal loading of samples at each age.  (B)  Expression of FAS increases in 
all animals from 21 to 28 days of age and is highest in fatties at 28 days of age.  This 
elevated level of protein expression begins to decrease by 60 days of age.  The age by 
phenotype interaction was significant at 28 and 60 days of age (P=0.0027 and P=0.0019, 
respectively).  
A 
B 
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Figure 11.  PPARγ expression in relation to insulin resistance at 21, 28 and 60 days 
of age.  18 µg of inguinal adipose protein extracts were prepared at each of the 3 ages, 
separated by 10% SDS-PAGE, and analyzed using a Western blot technique.  (A) PPARγ 
was detected as a 54 kD band.  Blots were quantified and mean optical densities of 7 
blots were analyzed and quantified.  β-actin is shown to demonstrate equal loading of 
samples at each age.  (B)  Expression of PPARγ  increases in all animals from 21 to 28 
days of age and is highest in fatties at 28 days of age (P=0.0003).  These levels remained 
elevated at 60 days of age (P=0.0040). 
A 
B 
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the same level as at 21 days of age, but FAS expression remains high in fatties.  By 60 
days of age PPARγ expression has increased further in leans, but PPARγ expression 
remains at about the same high level in fatties, at a level that is still higher than the leans.  
Thus PPARγ expression seems to be driven up rapidly after the onset of hyperphagia in 
fatties and remains high.  In lean rats, PPARγ expression increases more gradually with 
age.  These results were consistent with our hypothesis that PPARγ is upregulating 
lipogenic enzymes that may in turn be increasing insulin sensitivity after the onset of 
hyperphagia. 
Expression of FAS and PPARγ relative to the onset of hyperphagia.   
There is clearly a dramatic induction of both FAS and PPARγ proteins during the 
fourth week of life.  To determine the timing of these changes in expression relative to 
the onset of hyperphagia, rats were weighed daily through this interval, and killed by 
decapitation at days 21 through 28 for analysis of FAS and PPARγ expression in inguinal 
adipose tissue.   
FAS expression increases gradually from 21 to 28 days of age (Fig. 12).  FAS is 
significantly increased in fatties by 25 days of age and remains elevated through 28 days 
of age.  The induction of PPARγ followed a similar pattern to the induction of FAS from 
21 to 28 days of age, but is slightly delayed (Fig. 13).  PPARγ protein expression begins 
to increase in both genotype groups at 27 days of age and became significantly higher in 
fatties at 28 days of age.  These data indicate that changes in FAS and PPARγ expression 
follow a similar pattern, increasing in lean rats and in fatties within a few days of the  
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Figure 12.  FAS expression relative to the onset of hyperphagia.  FAS expression 
relative to the onset of hyperphagia.  (A)  18 µg of inguinal adipose protein extracts was 
prepared from each age between 21 to 28 days of age, separated by 8% SDS-PAGE, and 
analyzed using a Western blot technique.  β-actin is shown to demonstrate equal loading 
of samples at each age.  (B)  A picture of the Western blot was taken and bands were 
quantified densitometrically.  The data were analyzed as a degree of increase in optical 
density (OD) above zero.  Expression of FAS increases in all animals from 21 to 28 days 
of age and is highest in fatties, with the exception of day 27 were more data is needed.  
The age by phenotype interaction was significant at 25, 26, 27, and 28 days of age 
(P<0.0001, P<0.0001 P=0.0092, P<0.0001 respectively).   
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Figure 13.  PPARγ expression relative to the onset of hyperphagia.  PPARγ 
expression relative to the onset of hyperphagia. (A)  18 µg of inguinal adipose protein 
extracts was prepared from each age between 21 to 28 days of age, separated by 10% 
SDS-PAGE, and analyzed using a Western blot technique.  β-actin is shown to 
demonstrate equal loading of samples at each age (B)  A picture of the Western blot was 
taken and bands were quantified using densitometric quantitation.  The data was analyzed 
as a degree of increase in optical density (OD) above zero.  Expression of PPARγ 
corresponds to insulin tolerance test previously conducted in the lab.  At 23 days of age, 
when animals reach a peak in insulin resistance, PPARγ expression is the lowest.  After 
the onset of hyperphagia when fatties suddenly become insulin sensitive, PPARγ 
induction begins to increase and peaks at 28 days of age when fatties also reach a peak in 
insulin sensitivity.  The age by phenotype interaction was significant by 28 days of age 
(P<0.0001).  PPARγ expression appears to be rising later than FAS suggesting that it is 
responding to insulin but not determining the onset of hyperphagia.   
A 
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onset of hyperphagia.  This pattern is also similar to changes in insulin sensitivity that 
occur in this interval.   
Discussion 
In insulin resistant adult fatties, activation of PPARγ by thiazolidinediones 
increases insulin sensitivity by stimulating the expression of genes for lipogenesis in 
adipose tissue, leading to an increase in food intake and fat mass (4; 7).  We propose that 
a similar PPARγ mechanism is involved in activating hyperphagia and increasing insulin 
sensitivity in fatties early in life.   
Prior to this investigation, the best evidence to support this hypothesis derived 
from data on the effects of high and low fat diets on PPARγ and FAS mRNA expression.  
FAS mRNA is low during the suckling period and increases when pups are weaned onto a 
high carbohydrate diet (8; 132; 186; 187).  This rise in FAS mRNA is driven by a sharp 
increase in insulin; when animals are weaned onto a high fat diet, insulin levels remain 
low, and FAS mRNA is undetectable (8).  In contrast, adipose tissue PPARγ mRNA 
expression increases during the suckling period and reaches a plateau after weaning.  
Levels of PPARγ mRNA increase whether rats are weaned onto a high fat or high 
carbohydrate diet.  Therefore, it appears that expression of PPARγ mRNA is regulated by 
developmental mechanisms rather than diet composition (8; 9).  The combination of 
increasing insulin and increasing PPARγ expression could promote lipogenesis and 
insulin sensitivity in concert. 
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Rousseau et al found PPARγ mRNA levels increase during the third week of life, 
and reached its peak at 23 days of age, which corresponds with the age at which robust 
hyperphagia emerges in fatties (8).  Our data show that neither FAS or PPARγ mRNA are 
effected by the fatty genotype before the onset of hyperphagia.  However, both FAS and 
PPARγ mRNA are induced in fatty rats after the onset of hyperphagia.  This pattern 
occurs in rats that remain with their dams and are consuming solid food and nursing.  
Therefore, the induction of FAS and PPARγ mRNA are triggered by developmental 
factors and not by investigator initiated weaning.  The developmental factor that drives 
FAS expression is the increase in consumption of carbohydrates, which drives insulin 
secretion.  The developmental factor that drives PPARγ expression is unknown, but is 
apparently not the change in diet.  Leptin promotes insulin sensitivity by enhancing the 
expression of PPARγ in the adipose tissue of young and old rats (188).  However, the 
leptin signaling defect in fatties clearly is not resolved in this interval.  Furthermore, there 
are no differences in PPARγ expression prior to the onset of hyperphagia, even though 
leptin signaling is already impaired at this age (104).  Therefore changes in leptin 
signaling are not involved in the induction of PPARγ expression in this interval. 
Differences in glucose regulation are apparent across the weaning transition.  
Glucose infusion studies in suckling animals show that, despite higher glycemia and 
insulinemia, glucose utilization rate by tissues is much lower than in weaned animals, 
indicating that suckling rats are insulin resistant relative to weaned rats.  Glucose clamp 
studies also indicate insulin fails to stimulate whole-body glucose utilization during the 
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suckling period (177; 178).  When weaned onto a high carbohydrate diet these 
adaptations are reversed (189), as demonstrated by increased FAS expression.   
These differences in glucose regulation seen in wildtype rats are further 
exaggerated in fatty rats.  We have shown elsewhere that insulin sensitivity changes 
around the onset of hyperphagia in a complex pattern (Thesis Chapter 3).  Fatties are 
more insulin resistant than their lean littermates at 3 weeks of age, before the onset of 
hyperphagia, hyperinsulinemia and overt obesity.  Fatties and lean rats become 
increasingly insulin resistant from 21 to 23 days of age.  At 23 days of age, insulin 
resistance reaches a peak and fatties become hyperphagic at the same day.  After 23 days 
of age, fatties and leans become more insulin sensitive over the next couple of days, and 
they are as insulin sensitive as their lean littermates by 25 days of age.  Fatties and leans 
gradually become more insulin resistant over the next few weeks, with fatties becoming 
insulin resistant at a higher rate as they become obese.  The complex changes in insulin 
sensitivity around the onset of hyperphagia suggest that a developmental perturbation in 
insulin signaling occurs in this interval (Thesis Chapter 3). 
When animals are insulin resistant at 3 weeks of age, FAS and PPARγ expression 
levels are similar between lean and fatty rats.  It is likely that the early phase of insulin 
resistance that exists prior to the onset of hyperphagia primarily reflects minimal leptin 
signaling.  The role of leptin in insulin resistance is apparent in animals that lack adipose 
tissue.  These models also produce very little leptin and are insulin resistant.  Adipose 
tissue implants or exogenous leptin injections improve their insulin sensitivity (91).  
Exogenous leptin injections also improve insulin resistance in people with congenital 
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generalized lipodystrophies (80; 82).  These observations support the hypothesis that fatty 
rats develop insulin resistance early in life, before the onset of hyperinsulinemia and 
obesity, because of the reduction in leptin signaling.   
After the onset of hyperphagia both FAS and PPARγ protein expression are 
induced and fatties become as insulin sensitive as their lean littermates.  The time course 
of this change in FAS and PPARγ protein expression closely follows the time course of 
the change in insulin sensitivity.  These data suggest that changes in FAS and PPARγ are 
closely linked to change in insulin sensitivity and to each other.  FAS expression seems to 
increase earlier than PPARγ expression.   FAS levels are higher in fatties by 25 days of 
age, while PPARγ levels become higher in fatties by 28 days of age.  Several factors 
contribute to this delay.  First, the range of variation in FAS expression is greater than 
that of PPARγ.  Second, PPARγ levels rise in lean rats across this interval, making it 
more difficult to detect differences in expression.  It is also likely that changes in PPARγ 
ligand binding and signaling occur before changes in expression begin.  For these 
reasons, it is not possible to determine from these data whether increased PPARγ 
signaling occurs before or after the increase in FAS expression.  It should be noted that, 
because receptor defect in fatties is not resolved during this period, these changes must be 
mediated by a mechanism that is independent of leptin signaling. 
The portion of the leptin signal transduction pathway that regulates food intake 
does affect food intake during early postnatal development (121; 122).  However, recent 
work indicates that leptin affects the maturation of the arcuate nucleus of the 
hypothalamus (ARH) during this period (119).  Leptin normally functions to stimulate 
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the ARH neurons, reducing food intake later in life.  These data suggest leptin not only 
provides signals to the brain to mediate food intake, but also serves as a vital component 
in brain development associated with leptin signaling.  It is possible that the onset of 
hyperphagia is driven primarily by the maturation of these central pathways regulating 
food intake.  However, fatty rats can be induced to overeat as early as 12, 15 and 18 days 
of age under some experimental conditions, which suggests that other factors are also 
required to stimulate hyperphagia (123).  We propose that an interaction between the 
maturation of the central pathways for the regulation of food intake, and peripheral 
mechanisms regulating insulin signaling determines the onset of hyperphagia in fatties. 
The events occurring around the onset of hyperphagia can be depicted as a 
developmental cascade (Fig. 14).  During the first three weeks of age, fatties accumulate 
excess adipose tissue by thermoregulatory mechanisms.  From 21 to 23 days of age, 
fatties become increasingly insulin resistant, and at 23 days of age, fatties develop robust 
hyperphagia, hyperinsulinemia and increased growth rate.  After the onset of 
hyperphagia, FAS and PPARγ mRNA levels increase first, insulin sensitivity improves 
soon after, and FAS and PPARγ protein expression gradually increase.  These data 
strongly suggest that PPARγ is involved in the development of insulin sensitivity after 
the onset of hyperphagia.  The key to understanding the onset of hyperphagia could be 
found in the increasing insulin resistance that precedes it. 
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Figure 14. Developmental cascade. 
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PART 5.  SUMMARY AND CONCLUSIONS 
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The goal of this research was to determine the relationship between insulin 
sensitivity and the development of hyperphagia in the fatty rat.  Because fatties develop 
hyperphagia on a single day in postnatal development, this model system can be used to 
identify cellular and molecular mechanisms that contribute to the development of obesity 
in children.   
These experiments show a complex relationship between insulin sensitivity and 
hyperphagia.  Fatties experience two phases of insulin resistance, separated by a brief 
period of insulin sensitivity that follows the onset of hyperphagia.  The early phase of 
insulin resistance occurs before fatties are obese and probably represents the lack of 
leptin signaling.  During the later phase, insulin resistance becomes progressively greater 
as fatties become obese.  Fatties also become increasingly insulin resistant in the few 
days prior to the onset of hyperphagia, and insulin resistance peaks on the first day of 
hyperphagia.  After this peak fatties become as insulin sensitive as their littermates within 
two days.  These data suggest that some developmental perturbation of insulin signaling 
is related to the onset of hyperphagia.  
Several studies indicate the activation of pathways regulated by PPARγ promote 
insulin sensitivity and hyperphagia.  In insulin resistant adult fatties, activation of PPARγ 
by thiazolidinediones increases insulin sensitivity by stimulating the expression of genes 
for lipogenesis in adipose tissue, leading to an increase in food intake and fat mass (4; 7).  
Rousseau et al further demonstrated that the expression of PPARγ mRNA is regulated by 
developmental mechanisms rather than diet composition (8).  We proposed that a similar 
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PPARγ mechanism was involved in activating hyperphagia and increasing insulin 
sensitivity in fatties early in life.   
We examined the expression of PPARγ in inguinal adipose tissue during the 
development of hyperphagia.  PPARγ expression was low before the onset of 
hyperphagia.  PPARγ mRNA increased in fatties within two days of the onset of 
hyperphagia.  PPARγ protein levels increased more gradually after the onset of 
hyperphagia, becoming greater in fatties by 28 days of age.  The changes in PPARγ 
expression occur in parallel with the changes in insulin sensitivity in the period.  It is 
likley that changes in PPARγ signaling are more directly related to these changes. 
In summary we propose that an interaction between the maturation of the central 
pathways for the regulation of food intake, and peripheral mechanisms regulating insulin 
signaling determines the onset of hyperphagia is fatties.  The events occurring around the 
onset of hyperphagia can be depicted as a developmental cascade (Fig. 14).  During the 
first three weeks of life, fatties accumulate excess adipose tissue by thermoregulatory 
mechanisms.  From 21 to 23 days of age, fatties become increasingly insulin resistant, 
and at 23 days of age, fatties develop robust hyperphagia, hyperinsulinemia and increased 
growth rate.  After the onset of hyperphagia, FAS and PPARγ mRNA levels increase first, 
insulin sensitivity improves soon after, and FAS and PPARγ protein expression gradually 
increase. 
The prevalence of pediatric obesity in the United States has increased 
dramatically over the past two decades.  Our research shows that the development of 
hyperphagia in early life is dependent not only on central nervous systems pathways, but 
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also on peripheral metabolic pathways that mediate insulin sensitivity.  The fact that 
hyperphagia does not occur before the increase in PPARγ expression suggests that it is 
crucial that pathways involved in developmental alterations in insulin signaling and 
increased food intake be understood to develop effective interventions for the obesity 
epidemic.   
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A1.  Protocol:  Western Blot Analysis for Adipose Tissue 
 
I.  Preparation of Homogenizing Buffer and Protease Inhibitors 
A.  2 X Homogenizing Buffer Salts 
1.  Mix these salts in 45 ml water. 
a.  Add 0.7882 grams of 100 mM Tris HCl (M.W. 157.64). 
b.  Add  8.732 grams of 510 mM sucrose (M.W. 342.30). 
c.  Add  0.0292 grams of 2 mM EDTA (F.W. 292.25). 
2.  Adjust pH to 7.4. 
3.  Adjust volume to 50 ml. 
4.  Store at 4 degrees C. 
B.  Protease Inhibitors  
1.  Prepare stock solutions and store in 2 ml µl aliquots at -20ºC.  2 ml Protease 
Inhibitor aliquots should be discarded after approximately 3 uses to minimize breakdown 
after thawing multiple times.  
a.  2 µM phenylmethylsulfonyl fluoride (100X, Sigma P7626, F.W33.  
174.20) 
b.  1 µM pepstatin (250X, Sigma P4205, F.W. 685.90) 
c.  80 trypsin inhibitory units per ml of aprotinin or 200 µg/ml (100X, 
Sigma A1153) 
d.  10 µM leupeptin (100X, Sigma L2884, F.W. 475.60) 
e.  2 mM sodium orthovanadate (100X, Sigma S6508, F.W. 183.90) 
C.  Prepare homogenizing buffer with protease inhibitors. 
  121
1.  Prepare immediately before processing tissues.  Place all reagents on ice. Some 
reagents degrade rapidly when added to an aqueous solution. 
2.  Mix protease inhibitors with homogenizing buffer with the following volumes 
per 10 ml of final volume. 
 a.  5 ml 2X homogenizing buffer 
 b.  0.05 ml 1 mM PMSF 
 c.  aprotinin 
HOMOGENIZING BUFFER 
Volume to Make 10 Completed
1X Homogenizing Salts 5
Water 4.66
2 uM PMSF 0.05
80 trypsin inhibitory milliu 0.05
1 uM pepstatin 0.04
10 uM leupeptin 0.1
2 mM sodium orthovanadate 0.1
Final Volume 10  
 
II.  Preparation of adipose tissue extracts 
1.  Chill homogenizer generator in an ice bath prior to using it. 
2.  Prepare homogenizing buffer immediately before processing tissues.  All 
reagents should be on ice.  Some reagents degrade rapidly when added to an aqueous 
solution. 
3.  Add 1 ml of homogenization buffer per 1 gram of fat pad to each centrifuge 
tube. 
4.  Homogenize fat pad in the homogenization buffer while on ice.  
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5.  Centrifuge homogenates at 5000 x g for 2 minutes at 4ºC.  Remove debris and 
insoluble material; save the supernatant containing fat pad extracts.  
6.  Centrifuge homogenates at 13000 x g for 15 minutes at 4ºC.  Remove any 
debris and insoluble material, save the supernatant containing fat pad extracts.  
7.  Continue to centrifuge homogenates at 13000 x g for 15 minutes at 4ºC until 
all debris and insoluble material is removed, save the supernatant containing fat 
pad extracts.  
8.  Freeze tissue extracts at -80 ºC or quantify amount of protein in sample using 
the Bradford method. 
IV. Quantify adipose tissue extracts using the Bradford Method 
1.  Components: 
a.  1.5 ml BSA (0.5 mg/ml)  
b.  200 ml 0.15N NaCl 
c.  1 L Bradford Reagent 
d.  Store reagents at 4º C. 
2.  Into 5 separate microcuvette tubes, aliquot 0, 5, 10, 15 and 20 µl of 0.5 mg/ml 
BSA solution.   
3.  Pipette 5 µl of each unknown into microcuvettes. 
4.  Bring the volume of each to 100 µl with 0.15N NaCl. 
5.  Add to each tube, 1 ml Bradford Reagent and vortex.  Incubate at room 
temperature for 2 minutes. 
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5.  Measure Abs595  nm, using a 1 ml microcuvette.  Generate a standard curve by 
plotting Abs595  nm versus protein concentration. 
6.  For the unknown sample, use the standard curve as a reference to determine 
the concentration of the unknown sample.  If after the initial assay, the unknown protein 
concentration is too high, dilute the protein or assay a smaller aliquot of the unknown. 
 
X.  SDS-PAGE Electrophoresis. 
Gel electrophoresis  
Separate proteins using a 10% polyacrylamide gel according to the BioRad protocol for 
SDS– PAGE Laemmli (for discontinuous gels).  Load 21, 28 and 60 day old lean and 
obese sex matched animals onto gel.  
1.)  Pour 10% resolving gel (follow BioRad Mini-Protean 3 Cell instruction manual). 
Wait 45 minutes- 1 hour for gel to harden. 
2.) Pour stacking gel, and place 1.5mm combs into gel. (Follow BioRad Mini-Protean 
3 Cell instruction manual.) Wait 30 minutes for gel to harden. 
3.)  Load equal amounts of protein from 14, 21, and 28 day old sample extracts.  
Calculate appropriate amount of 5X sample loading buffer and water to mix with 
sample extract for equal loading volumes for each sample. Run samples on gel for 4 
hours at 50 volts. 
 
XI.  Western Blot Analysis  
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Follow BioRad Mini TransBlot Electrophoretic Transfer Cell instruction manual to 
conduct transfer. 
 After samples have run to completion, carefully remove gel and soak in transfer buffer.  
Proceed to pour transfer buffer containers with the filter pad and filter paper.  Equilibrate 
the membrane for 1 minute in methanol, wash in DDI water for 5 minutes,  and then 
place in container with transfer buffer.  Soak all items for 15-30 minutes. After 15-30 
minutes, immerse   in tank with ice chest.  Place tank on 4ºC.  Transfer gel to membrane 
for 5 hours at 100 volts, 400mAMP or overnight (11-15 hours) at 30 volts, 90 mAMP.  
Overnight transfers are preferred to ensure proteins are completely transferred and box 
does heat.   
 
XII.  PPARγ and Fatty Acid Synthase antibody  
Follow Cell Signal Protocol for PPARγ antibody  #2492.  Follow Santa Cruz Protocol for 
FAS antibody.  Add a 1: 500 dilution of primary antibody to membrane and a 1: 2000 
dilution of secondary antibody to membrane. 
 
XIII.  Western Blotting Luminol Reagent  
Follow Santa Cruz Protocol sc-2048.   
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SAS code 
Program 1.  Daily gain data analysis. 
libname XX 'c:/SASRUNS/XX'; 
   options  linesize  =  110;  options  pagesize  =  20000; 
   options nocenter;  options nodate; options nonumber; run; 
   data one; 
infile 'c:/SASRUNS/ArrayGroup/youngunsgain.txt' FIRSTOBS=2; 
input id lit sex geno G15-G24 ; 
*Change data to univariate format; 
y = G19; age = 19;  output; 
y = G20; age = 20;  output; 
y = G21; age = 21;  output; 
y = G22; age = 22;  output; 
y = G23; age = 23;  output; 
y = G24; age = 24;  output; 
drop G15-G24; 
run; 
proc sort; 
by id age; 
run; 
proc mixed method=ml scoring=150 info update itdetails; 
  class id lit sex geno age; 
  model y=geno|sex|age/noint; 
  random lit; 
  repeated age/ subject=id group=sex type=un; 
  parms/OLS; 
  lsmeans geno*age /diff slice=age; 
run; 
 
Dataset 1.  Daily gains. 
id  lit  sex  geno  G15  G16  G17  G18  G19  G20  G21  G22  G23  G24 
12380  1142  0  0  1.66  2.94  2.22  1.58  2.07  1.49  1.13  0.57  3.46  2.87 
12381  1142  0  2  1.59  2.24  2.02  1.66  2.05  0.90  1.43  1.56  3.66  4.98 
12382  1142  0  2  1.95  3.52  1.52  1.78  2.08  0.88  1.44  3.79  4.67  3.31 
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12383  1142  0  0  1.79  3.10  2.64  1.46  1.68  0.77  2.08  3.00  2.79  3.10 
12384  1142  0  2  1.89  2.43  2.13  1.60  1.80  1.08  1.07  0.66  5.89  2.96 
12385  1142  0  0  2.41  2.36  2.23  1.44  1.53  1.10  1.70  2.66  1.88  3.25 
12386  1142  0  2  1.60  3.15  1.98  1.73  1.79  0.93  1.25  3.94  3.42  3.92 
12387  1142  0  0  2.08  2.82  2.64  1.03  1.44  1.29  1.84  2.58  2.67  3.65 
12418  1146  0  0  3.12  1.70  1.65  1.61  2.18  1.94  1.70  2.50  2.34  3.32 
12419  1146  0  2  2.92  2.24  2.22  2.10  2.02  2.51  1.91  4.94  5.25  3.13 
12420  1146  0  2  2.87  1.79  1.65  1.86  2.37  1.88  2.34  4.03  4.77  4.11 
12421  1146  0  0  3.25  1.83  1.94  1.89  2.19  1.53  2.54  1.63  3.83  2.90 
12423  1146  0  2  2.72  2.02  1.75  1.51  2.03  1.30  2.84  3.21  3.79  4.18 
12425  1146  0  0  2.85  2.20  1.15  2.42  2.51  1.61  1.62  2.64  2.43  2.77 
12427  1146  1  2  3.64  2.08  1.51  1.67  2.25  1.94  2.14  1.07  6.57  5.05 
12428  1146  1  0  2.84  2.02  2.24  2.25  1.80  2.15  2.13  3.07  3.63  3.31 
12433  1147  0  2  2.23  2.23  1.11  1.91  1.37  2.14  0.77  0.37  3.04  4.60 
12434  1147  0  0  2.25  2.23  1.55  2.04  1.54  2.15  1.74  2.80  2.31  3.95 
12435  1147  0  2  2.29  1.93  1.53  1.78  0.91  1.58  1.13  1.22  4.17  4.94 
12436  1147  0  2  2.30  1.76  1.12  2.01  1.02  2.09  0.98  4.73  3.61  4.54 
12437  1147  0  0  1.99  2.27  1.40  2.35  1.61  2.03  1.69  2.66  2.07  4.09 
12438  1147  0  0  2.08  1.51  1.60  1.91  1.11  2.10  2.02  2.45  1.92  4.34 
12439  1147  0  1  2.20  2.45  1.52  2.02  1.54  2.12  1.86  2.17  1.75  3.92 
12440  1147  1  1  2.13  1.35  2.02  1.97  1.21  2.40  1.93  2.42  1.83  4.50 
12460  1149  0  1  2.82  1.12  2.39  0.92  1.88  1.58  2.21  2.24  3.23  4.30 
12461  1149  0  0  2.65  1.10  2.12  0.78  2.43  1.32  2.52  2.40  3.67  3.96 
12462  1149  0  1  2.91  1.29  2.28  1.31  2.10  1.61  2.32  2.86  2.03  4.63 
12464  1149  0  1  2.52  1.26  2.36  1.18  2.15  1.82  2.27  1.99  4.31  3.58 
12465  1149  0  1  2.95  1.26  1.74  1.35  2.27  1.84  2.02  2.60  3.46  3.54 
12467  1149  1  1  2.43  1.22  2.28  1.02  2.09  1.61  2.31  2.18  3.69  3.63 
12468  1149  1  1  2.70  1.52  2.27  1.30  2.64  1.41  3.16  2.61  4.21  4.65 
12469  1149  0  2  2.96  1.62  2.00  0.93  2.01  1.38  1.58  3.31  4.88  4.34 
12474  1150  0  2  2.46  2.23  1.40  1.96  1.05  1.83  1.14  3.11  4.73  4.79 
12475  1150  0  1  2.12  1.44  1.90  1.39  1.24  1.22  2.81  2.69  2.87  4.53 
12476  1150  0  1  2.40  2.29  1.81  2.19  1.13  2.08  2.39  2.94  2.64  5.10 
12477  1150  0  1  2.56  2.45  0.75  2.03  1.37  2.48  2.83  3.06  3.34  3.79 
12478  1150  1  0  2.79  2.27  1.61  2.08  1.52  1.70  2.46  3.26  2.95  3.45 
12481  1150  0  0  2.62  2.04  1.74  1.57  1.54  1.83  1.68  2.48  3.25  4.10 
12483  1150  1  1  3.04  2.63  1.57  1.71  1.63  2.29  2.52  3.15  3.86  4.22 
12485  1150  1  2  2.78  1.15  1.49  1.93  1.38  2.03  0.89  1.58  5.72  4.88 
12487  1151  0  0  3.05  1.41  1.56  1.88  1.61  1.85  .  .  .  .       
12488  1151  0  1  2.36  1.40  1.86  1.85  2.03  1.77  .  .  .  .           
12489  1151  0  1  2.58  1.63  2.22  1.73  2.18  1.25  .  .  .  .           
12490  1151  0  1  3.12  1.22  2.08  2.05  1.37  1.46  .  .  .  .           
12492  1151  0  2  2.21  1.51  1.71  1.67  1.03  1.98  .  .  .  .           
12494  1151  1  0  2.51  1.45  1.58  1.86  1.70  1.85  .  .  .  .           
12495  1151  1  2  2.48  1.49  2.09  1.90  1.23  1.88  .  .  .  .           
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12496  1151  1  0  2.07  1.75  1.95  2.35  1.77  2.05  .  .  .  .   
12498  1152  0  2  1.49  2.08  1.25  1.36  1.36  1.70  .  .  .  .   
12499  1152  0  0  1.51  1.19  1.79  1.70  1.15  2.38  .  .  .  .   
12500  1152  0  1  1.82  1.18  1.61  1.93  1.35  2.59  .  .  .  .   
12504  1152  1  2  2.12  1.52  1.67  1.53  0.89  1.83  .  .  .  .   
12505  1152  1  1  1.56  1.16  1.79  1.80  1.48  2.19  .  .  .  .   
12506  1152  1  0  2.22  1.27  1.68  2.69  0.88  3.01  .  .  .  .   
12507  1152  1  0  2.07  1.31  1.62  2.23  1.25  3.16  .  .  .  .   
12509  1152  1  2  2.21  0.89  1.82  1.75  1.29  1.53  .  .  .  .   
12511  1153  0  2  1.62  0.90  0.65  0.66  1.00  0.68  .  .  .  .   
12512  1153  0  1  1.71  0.75  0.80  1.45  0.92  1.05  .  .  .  .   
12513  1153  0  0  1.35  0.87  1.23  0.93  2.02  2.18  .  .  .  .   
12514  1153  0  2  1.52  1.05  1.01  1.42  1.24  1.42  .  .  .  .   
12515  1153  0  1  1.56  0.48  0.82  1.05  1.88  2.00  .  .  .  .   
12516  1153  0  1  1.30  1.16  0.84  0.93  1.33  1.43  .  .  .  .   
12517  1153  0  0  1.17  0.87  1.19  1.52  2.77  1.81  .  .  .  .   
12519  1153  1  1  1.00  1.09  0.63  1.57  1.30  1.57  .  .  .  .   
12554  1157  0  2  1.78  1.71  2.12  1.50  1.19  1.34  .  .  .  .   
12556  1157  0  1  2.01  1.38  1.87  1.21  1.02  2.36  .  .  .  .   
12557  1157  0  0  2.67  1.46  1.36  1.65  0.87  2.20  .  .  .  .   
12563  1157  1  0  1.52  2.08  2.19  1.53  1.22  2.30  .  .  .  .   
12564  1157  0  0  1.88  1.65  1.77  1.44  1.43  1.50  .  .  .  .   
12565  1157  1  2  1.65  2.03  1.71  1.91  0.96  1.85  .  .  .  .   
12566  1157  1  0  2.19  1.87  1.79  1.74  1.11  1.73  .  .  .  .   
12567  1157  1  0  2.09  1.69  1.97  1.46  1.47  1.97  .  .  .  .   
12608  1162  0  0  1.64  1.78  0.67  1.46  1.40  1.47  .  .  .  .   
12609  1162  0  0  2.23  1.11  1.29  1.30  1.39  1.87  .  .  .  .   
12610  1162  0  2  2.16  2.04  0.80  1.49  1.21  2.06  .  .  .  .   
12611  1162  0  0  2.15  2.00  0.70  1.55  0.79  1.76  .  .  .  .   
12614  1162  1  0  1.85  2.15  1.07  1.67  1.22  2.15  .  .  .  .   
12616  1162  1  2  1.89  2.31  0.59  1.46  0.89  1.38  .  .  .  .   
12617  1162  1  0  2.27  1.56  0.98  1.46  1.32  1.51  .  .  .  .   
12618  1162  1  2  2.49  1.73  1.18  1.30  1.24  1.76  .  .  .  .         
12633  1164  0  1  2.84  1.50  0.95  2.76  1.74  1.64  3.64  2.48  2.79  4.49 
12635  1164  0  1  2.75  1.44  1.28  2.42  1.94  1.42  2.28  2.32  2.77  3.42 
12637  1164  0  1  2.67  1.89  1.46  2.24  1.71  2.91  2.36  2.72  3.74  4.24 
12638  1164  1  1  2.58  1.67  1.43  2.49  1.92  2.09  3.05  2.03  3.43  3.67 
12639  1164  1  2  2.23  1.52  1.41  2.50  1.69  1.33  2.70  2.09  3.54  3.54 
12640  1164  1  1  3.01  1.87  1.52  2.40  2.09  2.51  3.64  2.86  3.61  3.55 
12641  1164  1  0  2.55  1.82  1.47  2.17  2.03  1.90  3.32  2.39  2.35  4.54 
12644  1165  0  1  3.47  1.66  2.25  1.37  2.12  2.63  3.06  2.15  2.03  3.54 
12646  1165  1  0  3.02  2.06  2.05  2.29  3.38  2.48  4.08  2.50  2.83  3.10 
12647  1165  0  0  2.78  2.33  2.40  1.57  2.44  2.37  3.27  2.35  3.06  2.95 
12649  1165  1  1  3.29  2.35  2.34  1.97  2.53  3.15  3.62  2.32  3.26  3.52 
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12650  1165  1  2  2.76  2.37  1.94  2.05  2.16  2.95  4.25  4.14  3.68  4.45 
12651  1165  1  2  2.63  2.01  1.82  2.28  1.97  2.79  3.80  4.65  3.43  4.07 
12652  1165  1  0  3.30  2.21  2.18  1.97  2.76  3.05  3.04  1.98  2.72  2.50 
12655  1166  0  1  2.76  1.35  1.81  2.42  1.57  1.55  2.96  2.10  3.64  3.51 
12656  1166  0  2  2.12  1.29  1.96  2.13  1.69  1.80  3.68  2.95  4.71  3.21 
12657  1166  0  1  2.78  1.36  1.73  2.47  1.23  2.35  2.88  1.54  3.88  3.51 
12658  1166  0  1  2.78  1.28  2.14  1.91  0.80  2.64  2.35  1.77  3.49  2.52 
12662  1166  1  0  2.96  1.63  1.68  2.54  2.28  2.03  2.95  1.76  4.24  2.71 
12663  1166  1  0  2.39  1.81  0.96  2.43  1.36  1.95  3.20  1.92  3.06  3.13 
12664  1166  1  1  2.36  1.58  2.14  1.62  2.26  1.87  3.12  2.08  3.50  3.28 
12665  1166  1  2  2.75  1.48  1.90  1.93  1.37  2.27  3.06  3.56  5.62  3.86 
12667  1167  0  2  1.62  1.13  2.19  1.92  1.41  1.84  2.20  3.79  4.11  . 
12668  1167  0  2  2.09  1.45  2.45  2.17  1.78  1.74  2.92  4.91  3.64  . 
12669  1167  1  1  1.83  1.57  1.70  2.59  1.74  2.04  3.51  3.36  3.23  . 
12670  1167  1  0  1.45  1.70  2.59  2.48  2.53  2.98  3.08  2.85  2.69  . 
12671  1167  1  1  2.00  1.35  2.90  2.56  2.21  3.50  3.62  3.58  3.68  . 
12672  1167  1  1  2.24  1.80  2.90  2.49  2.56  2.24  3.12  3.03  3.01  . 
12675  1167  1  0  1.82  1.24  2.79  2.14  1.77  2.31  3.71  2.83  3.79  2.79 
12676  1167  1  2  2.29  1.92  2.82  1.93  1.67  2.12  3.20  3.20  5.33  3.23 
12789  1178  0  1  1.97  1.40  1.02  1.74  1.00  3.53  1.87  3.53  4.69  2.57 
12790  1178  0  0  1.84  2.08  0.76  1.40  0.96  2.23  3.10  3.02  4.05  3.06 
12791  1178  0  1  2.04  0.99  1.03  1.53  0.47  2.15  2.22  3.08  4.51  3.04 
12792  1178  0  2  2.40  1.21  1.10  1.54  1.17  1.78  1.68  2.07  6.03  4.20 
12793  1178  0  2  1.54  1.19  0.72  1.43  0.51  2.11  0.83  4.43  2.74  4.31 
12795  1178  0  0  1.84  1.23  1.14  1.37  0.73  2.11  1.66  2.22  4.39  3.45 
12797  1178  1  0  2.58  1.63  0.62  1.66  1.08  2.27  2.52  3.54  3.63  3.82 
12799  1178  1  2  2.04  1.31  1.14  1.83  0.08  1.69  0.37  2.42  4.32  4.71 
 
Program 2.  Tissue weights data analysis.   
 
libname XX 'c:/SASRUNS/XX'; 
   options  linesize  =  110;  options  pagesize  =  20000; 
   options nocenter;  options nodate; options nonumber; run; 
   data one; 
infile 'c:/SASRUNS/ArrayGroup/tissues.txt' FIRSTOBS=2; 
input id  lit  sex  geno  age  body ing  stom  empty  contents  liver; 
run; 
proc mixed method=ml scoring=150 info update itdetails; 
  class id lit sex geno age; 
  model body=geno|sex|age/noint; 
  random lit/ group=sex; 
  lsmeans geno*age /diff slice=age; 
run; 
proc mixed method=ml scoring=150 info update itdetails; 
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  class id lit sex geno age; 
  model ing=geno|sex|age/noint; 
  random lit/ group=sex; 
  lsmeans geno*age /diff slice=age; 
run; 
proc mixed method=ml scoring=150 info update itdetails; 
  class id lit sex geno age; 
  model stom=geno|sex|age/noint; 
  random lit/ group=sex; 
  lsmeans geno*age /diff slice=age; 
run; 
proc mixed method=ml scoring=150 info update itdetails; 
  class id lit sex geno age; 
  model empty=geno|sex|age/noint; 
  random lit/ group=sex; 
  lsmeans geno*age /diff slice=age; 
run; 
proc mixed method=ml scoring=150 info update itdetails; 
  class id lit sex geno age; 
  model contents=geno|sex|age/noint; 
  random lit/ group=sex; 
  lsmeans geno*age /diff slice=age; 
run; 
proc mixed method=ml scoring=150 info update itdetails; 
  class id lit sex geno age; 
  model liver=geno|sex|age/noint; 
  random lit/ group=sex; 
  lsmeans geno*age /diff slice=age; 
run; 
 
Dataset 3.  Tissue weights. 
 
id         litter   sex  genotype   age       body  inguinal  stom   empty  content liver 
12380 1142 0 0 24 45.71 0.600 0.639 0.372 0.267 1.630  
12381 1142 0 2 24 48.97 1.261 2.100 0.344 1.756 2.034  
12382 1142 0 2 24 50.25 1.397 1.852 0.569 1.283 2.086  
12383 1142 0 0 24 47.51 0.623 1.406 0.317 1.089 1.617  
12384 1142 0 2 24 44.81 0.965 2.183 0.337 1.846 1.956  
12385 1142 0 0 24 45.43 0.603 1.194 0.313 0.881 1.550  
12386 1142 0 2 24 48.04 1.170 2.542 0.342 2.200 2.027  
12387 1142 0 0 24 47.57 0.530 1.515 0.466 1.049 1.648  
12418 1146 0 0 24 48.44 0.315 1.846 0.396 1.450 1.411  
12419 1146 0 2 24 57.03 1.467 3.185 0.502 2.683 2.741  
12420 1146 0 2 24 54.92 1.276 2.316 0.520 1.796 2.268  
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12421 1146 0 0 24 51.22 0.735 1.453 0.406 1.047 1.946  
12423 1146 0 2 24 53.40 1.385 2.428 0.387 2.041 2.371  
12425 1146 0 0 24 50.26 0.765 1.628 0.420 1.208 1.760  
12427 1146 1 2 24 56.92 1.354 3.353 0.423 2.930 2.604  
12428 1146 1 0 24 53.81 0.666 1.258 0.388 0.870 2.181  
12433 1147 0 2 24 40.76 0.904 1.313 0.343 0.970 1.780  
12434 1147 0 0 24 47.32 0.610 1.259 0.460 0.799 1.884  
12435 1147 0 2 24 47.10 1.264 2.071 0.357 1.714 2.160  
12436 1147 0 2 24 50.80 1.198 2.218 0.370 1.848 2.333  
12437 1147 0 0 24 48.59 0.610 1.326 0.378 0.948 1.997  
12438 1147 0 0 24 45.41 0.555 1.399 .394 1.005 1.600  
12461 1149 0 0 24 50.54 0.542 1.690 0.399 1.291 2.017  
12469 1149 0 2 24 52.29 1.352 2.043 0.398 1.645 2.464  
12474 1150 0 2 24 50.50 1.183 1.302 0.392 0.910 2.376  
12478 1150 1 0 24 49.13 0.540 0.961 0.650 0.311 1.903  
12481 1150 0 0 24 48.01 0.225 1.658 0.388 1.270 2.011  
12485 1150 1 2 24 49.44 0.988 2.767 0.389 2.378 2.376  
12487 1151 0 0 20 36.42 0.316 1.284 0.266 1.018 1.212  
12492 1151 0 2 20 32.86 0.770 0.975 0.130 0.845 1.026  
12494 1151 1 0 20 36.30 0.302 1.222 0.234 0.988 1.300  
12495 1151 1 2 20 37.70 0.838 0.750 0.251 0.499 1.220  
12498 1152 0 2 20 35.30 0.829 1.055 0.452 0.603 1.244  
12499 1152 0 0 20 37.12 0.322 1.013 0.275 0.738 1.270  
12504 1152 1 2 20 38.90 0.856 1.122 0.275 0.847 1.330  
12506 1152 1 0 20 38.43 0.339 1.258 0.379 0.879 1.359  
12507 1152 1 0 20 38.52 0.361 1.318 0.268 1.050 1.368  
12509 1152 1 2 20 36.31 0.834 1.215 0.268 0.947 1.324  
12511 1153 0 2 20 30.13 0.558 0.728 0.210 0.518 0.939  
12513 1153 0 0 20 32.89 0.217 1.117 0.254 0.863 1.079  
12514 1153 0 2 20 32.99 0.660 1.118 0.256 0.862 0.987  
12517 1153 0 0 20 32.92 0.296 1.433 0.267 1.166 1.206  
12554 1157 0 2 20 35.52 0.820 0.641 0.230 0.411 1.242  
12557 1157 0 0 20 33.76 0.367 1.004 0.260 0.744 1.189  
12563 1157 1 0 20 34.32 0.360 1.116 0.228 0.888 1.197  
12564 1157 0 0 20 33.30 0.314 0.913 0.238 0.675 1.141  
12565 1157 1 2 20 32.59 0.616 0.970 0.204 0.766 1.107  
12566 1157 1 0 20 34.14 0.337 1.119 0.493 0.626 1.108  
12567 1157 1 0 20 34.88 0.350 1.088 0.224 0.864 1.241  
12610 1162 0 2 20 35.26 0.755 1.169 0.224 0.945 1.224  
12611 1162 0 0 20 32.55 0.292 1.056 0.268 0.788 0.199  
12614 1162 1 0 20 33.68 0.244 1.384 0.241 1.143 1.178  
12616 1162 1 2 20 35.28 0.758 1.079 0.291 0.788 1.279  
12617 1162 1 0 20 35.04 0.293 1.395 0.259 1.136 1.257  
12618 1162 1 2 20 34.62 0.706 1.048 0.209 0.839 1.102  
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12639 1164 1 2 24 48.95 1.406 1.869 0.326 1.543 1.824  
12641 1164 1 0 24 48.18 0.566 1.831 0.380 1.451 1.977  
12646 1165 1 0 24 55.86 0.903 2.059 0.375 1.684 2.073  
12650 1165 1 2 24 59.25 1.824 2.833 0.415 2.418 2.640  
12651 1165 1 2 24 58.33 1.816 2.331 0.443 1.888 2.584  
12652 1165 1 0 24 53.97 0.849 1.669 0.384 1.285 2.131  
12662 1166 1 0 24 48.95 0.679 1.876 0.365 1.511 2.009  
12665 1166 1 2 24 56.04 1.459 2.853 0.406 2.447 2.558  
12675 1167 1 0 24 52.06 0.630 0.853 0.426 0.427 1.960  
12676 1167 1 2 24 55.34 1.358 0.851 0.396 0.455 2.387  
 
 
Program 3. RT-PCR expression data analysis. 
 
libname XX 'c:/SASRUNS/XX'; 
   options  linesize  =  110;  options  pagesize  =  20000; 
   options nocenter;  options nodate; options nonumber; run; 
   data one; 
infile 'c:/SASRUNS/ArrayGroup/RTPCRdata.txt' FIRSTOBS=2; 
input id  lit  geno  age  FAS PPARG; 
run; 
proc mixed; 
  class id lit geno age; 
  model FAS=geno|age/noint; 
  lsmeans geno*age /diff slice=age; 
run; 
proc mixed; 
  class id lit geno age; 
  model PPARG=geno|age/noint; 
  lsmeans geno*age /diff slice=age; 
run; 
 
Dataset 3.  RTPCR data. 
 
id litter sex   genotype age FAS PPAR 
12380 1142 F 0 24 0.0819 0.9250 
12381 1142 F 2 24 4.0527 3.0227 
12382 1142 F 2 24 7.3692 2.5564 
12383 1142 F 0 24 0.1063 1.0940 
12384 1142 F 2 24 4.9019 2.3369 
12385 1142 F 0 24 0.2579 1.0060 
12418 1146 F 0 24 0.1255 0.8071 
12419 1146 F 2 24 4.9180 2.7210 
12420 1146 F 2 24 4.7169 1.7536 
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12421 1146 F 0 24 0.3735 1.4516 
12423 1146 F 2 24 4.4104 2.8401 
12425 1146 F 0 24 0.1835 1.2530 
12427 1146 M 2 24 1.0747 1.3852 
12428 1146 M 0 24 0.3864 1.0693 
12478 1150 M 0 24 0.6639 3.1742 
12485 1150 M 2 24 4.0651 2.6825 
12487 1151 F 0 20 0.0602 0.6076 
12492 1151 F 2 20 0.1301 1.1572 
12494 1151 M 0 20 0.0630 0.6706 
12495 1151 M 2 20 0.1018 0.8918 
12498 1152 F 2 20 0.3995 1.0887 
12499 1152 F 0 20 0.1347 0.6801 
12504 1152 M 2 20 0.1049 0.5714 
12506 1152 M 0 20 0.2102 0.5209 
12507 1152 M 0 20 0.1627 0.7350 
12509 1152 M 2 20 0.1832 0.9311 
12511 1153 F 2 20 0.0905 0.4755 
12513 1153 F 0 20 0.1316 0.5074 
12514 1153 F 2 20 0.1483 0.6598 
12554 1157 F 2 20 0.2139 0.6687 
12557 1157 F 0 20 0.1286 0.4705 
12610 1162 F 2 20 . 0.2239 
12611 1162 F 0 20 0.0707 0.4720 
12614 1162 M 0 20 0.0943 0.6170 
12616 1162 M 2 20 0.1068 1.2944 
12617 1162 M 0 20 0.0806 0.4510 
12618 1162 M 2 20 0.1405 1.0534 
12639 1164 M 2 24 0.8485 1.1207 
12641 1164 M 0 24 0.4359 0.7876 
12646 1165 M 0 24 0.0842 0.4380 
12651 1165 M 2 24 2.8248 1.4908 
12652 1165 M 0 24 0.1927 1.1696 
12662 1166 M 0 24 0.2481 0.6819 
12665 1166 M 2 24 2.1343 1.1220 
12675 1167 M 0 24 0.3783 0.5053 
12676 1167 M 2 24 1.7615 0.5233 
 
 
 
 
Program 4.  Data analysis of developmental changes in FAS protein expression. 
 
libname XX 'c:/SASRUNS/XX'; 
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   options  linesize  =  110;  options  pagesize  =  20000; 
   options nocenter;  options nodate; options nonumber; run; 
   data one; 
infile 'c:/SASRUNS/WESTERNS/FAS3day2.txt' FIRSTOBS=2; 
input age sex $ pheno $ blot OD; 
run; 
proc mixed; 
  class age pheno blot; 
  model OD=age|pheno; 
  random blot/group= age; 
  lsmeans pheno*age/slice = age; 
run; 
 
 
Dataset 4.  Optical densities. 
  
21 M L 1 0.0118044 
21 M O 1 0 
21 M L 2 0.056297 
21 M O 2 0.079956 
21 F L 3 0.0129866 
21 F O 3 0 
21 M L 4 0.187917 
21 M O 4 0.0655556 
21 F L 5 0.0582721 
21 F O 5 0.156208 
28 M L 1 0.125252 
28 M O 1 0.365409 
28 M L 2 0.25652 
28 M O 2 0.55606 
28 F L 3 0.0807006 
28 F O 3 0.0977968 
28 M L 4 0.261495 
28 M O 4 0.511643 
28 F L 5 0.273566 
28 F O 5 0.491966 
60 M L 1 0.270552 
60 M O 1 0.646922 
60 M L 2 0.0744017 
60 M O 2 0.314155 
60 F L 3 0.0215855 
60 F O 3 0.0844441 
60 M L 4 0 
60 M O 4 0.0482319 
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60 F L 5 0.0656534 
60 F O 5 0.416643 
 
 
 
Program 5.  Data analysis of developmental changes in PPAR γ protein expression. 
 
libname XX 'c:/SASRUNS/XX'; 
   options  linesize  =  110;  options  pagesize  =  20000; 
   options nocenter;  options nodate; options nonumber; run; 
   data one; 
infile 'c:/SASRUNS/WESTERNS/PPAR3ages.txt' FIRSTOBS=1; 
input age sex $ pheno $ blot OD; 
run; 
proc mixed; 
  class age pheno blot; 
  model OD=age|pheno; 
  random blot/group= age; 
  lsmeans pheno*age/slice = age; 
run; 
 
Dataset 5.  Optical densities. 
 
21 M L 1 0 
21 M O 1 0 
21 F L 2 0 
21 F O 2 0 
21 F L 3 0.104963 
21 F O 3 0.124392 
21 F L 4 0.123372 
21 F O 4 0.052176 
21 F L 5 0.084525 
21 F O 5 0.005445 
21 F L 6 0.01687 
21 F O 6 0.023101 
21 M L 6 0 
21 M O 6 0.111621 
21 M L 7 0.0682472 
21 M O 7 0.041754 
28 M L 1 0.047868 
28 M O 1 0.3406 
28 F L 2 0 
28 F O 2 0.072445 
28 F L 3 0.112018 
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28 F O 3 0.342657 
28 F L 4 0.040115 
28 F O 4 0.089164 
28 F L 5 0 
28 F O 5 0.17479 
28 F L 6 0.111621 
28 F O 6 0.114884 
28 M L 6 0.171476 
28 M O 6 0.226076 
28 M L 7 0.07749 
28 M O 7 0.246342 
60 M L 1 0.279382 
60 M O 1 0.406315 
60 F L 2 0.022131 
60 F O 2 0.121289 
60 F L 3 0.228799 
60 F O 3 0.23975 
60 F L 4 0.050606 
60 F O 4 0.07755 
60 F L 5 0 
60 F O 5 0.1232 
60 F L 6 0.038552 
60 F O 6 0.068248 
60 M L 6 0.107077 
60 M O 6 0.264347 
60 M L 7 0.257442 
60 M O 7 0.469979 
 
 
Program 5.  Data analysis of FAS protein expression relative to the onset of 
hyperphagia. 
 
libname XX 'c:/SASRUNS/XX'; 
   options  linesize  =  110;  options  pagesize  =  20000; 
   options nocenter;  options nodate; options nonumber; run; 
   data one; 
infile 'c:/SASRUNS/WESTERNS/FASinterval2.txt' FIRSTOBS=1; 
input age sex $ pheno $ blot OD; 
run; 
proc mixed; 
  class age pheno blot; 
  model OD=age|pheno; 
  random blot/group= age; 
  lsmeans pheno*age/slice = age; 
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run; 
 
 
Dataset 5.  Optical densities. 
   
21 M L 1 0.0141041 
21 M O 1 0.0226174 
21 M L 2 0.00829203 
21 M O 2 0 
21 F L 3 0.0222799 
21 F O 3 0.00403722 
21 M L 4 0 
21 M O 4 0 
21 M L 5 0.12937 
21 M O 5 0.330576 
22 M L 1 0.0257382 
22 M O 1 0.0325572 
22 M L 2 0 
22 M O 2 0.00594738 
22 F L 3 0 
22 F O 3 0 
22 M L 4 0 
22 M O 4 0.0203361 
22 M L 5 0.22741 
22 M O 5 0.337275 
23 M L 1 0.0215845 
23 M O 1 0.0250187 
23 M L 2 0.0113241 
23 M O 2 0.0606475 
23 F L 3 0.00531113 
23 F O 3 0 
23 M L 4 0 
23 M O 4 0.0015488 
23 M L 5 0.280486 
23 M O 5 0.419404 
24 M L 1 0.0325804 
24 M O 1 0.0404937 
24 M L 2 0.0746487 
24 M O 2 0.071483 
24 F L 3 0 
24 F O 3 0 
24 M L 4 0.0275443 
24 M O 4 0.266017 
24 M L 5 0.11132 
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24 M O 5 0.169256 
25 M L 1 0.0299619 
25 M O 1 0.0719539 
25 M L 2 0.0363862 
25 M O 2 0.29378 
25 F L 3 0.0783712 
25 F O 3 0.0394461 
25 M L 4 0.087554 
25 M O 4 0.351943 
25 M L 5 0.179928 
25 M O 5 0.305041 
26 M L 1 0.0585733 
26 M O 1 0.122725 
26 M L 2 0.388048 
26 M O 2 0.470556 
26 F L 3 0.0584837 
26 F O 3 0.259117 
26 M L 4 0.116544 
26 M O 4 0.401669 
26 M L 5 0.201887 
26 M O 5 0.223659 
27 M L 1 0.0368975 
27 M O 1 0.0593664 
27 M L 2 0.130568 
27 M O 2 0.2877 
27 M L 4 0.00775261 
27 M O 4 0.0915266 
27 M L 5 0.262853 
27 M O 5 0.544017 
28 M L 1 0.0284616 
28 M O 1 0.328512 
28 M L 2 0.165723 
28 M O 2 0.4493 
28 F L 3 0.1544 
28 F O 3 0.367791 
28 M L 4 0.167394 
28 M O 4 0.480243 
28 M L 5 0.0299756 
28 M O 5 0.66078 
 
Program 6.  Data analysis of PPAR γ protein expression relative to the onset of 
hyperphagia. 
 
libname XX 'c:/SASRUNS/XX'; 
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   options  linesize  =  110;  options  pagesize  =  20000; 
   options nocenter;  options nodate; options nonumber; run; 
   data one; 
infile 'c:/SASRUNS/WESTERNS/PPARinterval2.txt' FIRSTOBS=1; 
input age sex $ pheno $ blot OD; 
run; 
proc mixed; 
  class age pheno blot; 
  model OD=age|pheno; 
  random blot/group= age; 
  lsmeans pheno*age/slice = age; 
run; 
 
Dataset 6.  Optical densities.   
 
21 M L 1 0 
21 M O 1 0.0247159 
21 M L 2 0 
21 M O 2 0 
21 M L 3 0.029348 
21 M O 3 0.00470846 
21 F L 4 0.000710212 
21 F O 4 0.0224767 
21 F L 5 0.269699 
21 F O 5 0.303174 
21 F L 6 0.0934748 
21 F O 6 0.101685 
21 F L 7 . 
21 F O 7 . 
22 M L 1 0 
22 M O 1 0.0141936 
22 M L 2 0 
22 M O 2 0.00132742 
22 M L 3 0.0342412 
22 M O 3 0.0432273 
22 F L 4 0.0574618 
22 F O 4 0.0496434 
22 F L 5 0.275433 
22 F O 5 0.141537 
22 F L 6 0.0816291 
22 F O 6 0.0479148 
22 F L 7 . 
22 F O 7 . 
23 M L 1 0.0425565 
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23 M O 1 0.0291472 
23 M L 2 0.00166817 
23 M O 2 0.00794407 
23 M L 3 0.026836 
23 M O 3 0.076076 
23 F L 4 0.0126551 
23 F O 4 0.0122281 
23 F L 5 0.157849 
23 F O 5 0.0587771 
23 F L 6 0.0699772 
23 F O 6 0.0288646 
23 F L 7 . 
23 F O 7 . 
24 M L 1 0 
24 M O 1 0 
24 M L 2 0.0505263 
24 M O 2 0.108164 
24 M L 3 0.0623579 
24 M O 3 0.150528 
24 F L 4 0.0316361 
24 F O 4 0.0746361 
24 F L 5 0.0767623 
24 F O 5 0 
24 F L 6 0.0554279 
24 F O 6 0.0229594 
24 F L 7 . 
24 F O 7 . 
25 M L 1 0 
25 M O 1 0 
25 M L 2 0.0255029 
25 M O 2 0.0109833 
25 M L 3 0.0121242 
25 M O 3 0.0647869 
25 F L 4 0 
25 F O 4 0 
25 M L 5 0.0687502 
25 M O 5 0.121474 
25 M L 6 0.104195 
25 M O 6 0.0381804 
25 F L 7 0.0347957 
25 F O 7 0.0564576 
26 M L 1 0 
26 M O 1 0.0428774 
26 M L 2 0 
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26 M O 2 0.00703042 
26 M L 3 0.0504534 
26 M O 3 0.0904056 
26 F L 4 0 
26 F O 4 0 
26 M L 5 0.116526 
26 M O 5 0.0677189 
26 M L 6 0.0355528 
26 M O 6 0.0735313 
26 F L 7 0.0102024 
26 F O 7 0.0468601 
27 M L 1 0.00298176 
27 M O 1 0.196812 
27 M L 2 0 
27 M O 2 0 
27 M L 3 0.0727615 
27 M O 3 0.0713798 
27 F L 4 0 
27 F O 4 0.0208481 
27 M L 5 0.133009 
27 M O 5 0.230111 
27 M L 6 0.307325 
27 M O 6 0.355454 
27 F L 7 0.0468935 
27 F O 7 0.0899623 
28 M L 1 0.00681094 
28 M O 1 0.338871 
28 M L 2 0.00310534 
28 M O 2 0.101991 
28 M L 3 0.0302741 
28 M O 3 0.244235 
28 F L 4 0.0501374 
28 F O 4 0.235733 
28 M L 5 0.275609 
28 M O 5 0.33179 
28 M L 6 0.286908 
28 M O 6 0.546089 
28 F L 7 0.0770787 
28 F O 7 0.205225 
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